<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1-3.dtd?><?SourceDTD.Version 1.3?><?ConverterInfo.XSLTName jats2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8657839</article-id><article-id pub-id-type="doi">10.3390/ijms222312636</article-id><article-id pub-id-type="publisher-id">ijms-22-12636</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Midecamycin Is Inactivated by Several Different Sugar Moieties at Its Inactivation Site</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Ru</given-names></name><xref rid="af1-ijms-22-12636" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Hong</surname><given-names>Li-Li</given-names></name><xref rid="af2-ijms-22-12636" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Zhong-Ke</given-names></name><xref rid="af1-ijms-22-12636" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Ke-Meng</given-names></name><xref rid="af1-ijms-22-12636" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9621-3769</contrib-id><name><surname>He</surname><given-names>Wei-Qing</given-names></name><xref rid="af1-ijms-22-12636" ref-type="aff">1</xref><xref rid="c1-ijms-22-12636" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6281-6094</contrib-id><name><surname>Kong</surname><given-names>Jian-Qiang</given-names></name><xref rid="af2-ijms-22-12636" ref-type="aff">2</xref><xref rid="c1-ijms-22-12636" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Chizhov</surname><given-names>Alexander O.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-22-12636"><label>1</label>NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences &#x00026; Peking Union Medical College, Beijing 100050, China; <email>linru0905@163.com</email> (R.L.); <email>jiangzhongke@126.com</email> (Z.-K.J.); <email>polarismki@163.com</email> (K.-M.L.)</aff><aff id="af2-ijms-22-12636"><label>2</label>Institute of Materia Medica, Chinese Academy of Medical Sciences &#x00026; Peking Union Medical College (State Key Laboratory of Bioactive Substance and Function of Natural Medicines &#x00026; NHC Key Laboratory of Biosynthesis of Natural Products), Beijing 100050, China; <email>honglili@imm.ac.cn</email></aff><author-notes><corresp id="c1-ijms-22-12636"><label>*</label>Correspondence: <email>heweiqing@imb.pumc.edu.cn</email> (W.-Q.H.); <email>jianqiangk@imm.ac.cn</email> (J.-Q.K.)</corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>11</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2021</year></pub-date><volume>22</volume><issue>23</issue><elocation-id>12636</elocation-id><history><date date-type="received"><day>10</day><month>11</month><year>2021</year></date><date date-type="accepted"><day>21</day><month>11</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2021 by the authors.</copyright-statement><copyright-year>2021</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Glycosylation inactivation is one of the important macrolide resistance mechanisms. The accumulated evidences attributed glycosylation inactivation to a glucosylation modification at the inactivation sites of macrolides. Whether other glycosylation modifications lead to macrolides inactivation is unclear. Herein, we demonstrated that varied glycosylation modifications could cause inactivation of midecamycin, a 16-membered macrolide antibiotic used clinically and agriculturally. Specifically, an actinomycetic glycosyltransferase (GT) OleD was selected for its glycodiversification capacity towards midecamycin. OleD was demonstrated to recognize UDP-D-glucose, UDP-D-xylose, UDP-galactose, UDP-rhamnose and UDP-<italic toggle="yes">N</italic>-acetylglucosamine to yield corresponding midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-glycosides, most of which displayed low yields. Protein engineering of OleD was thus performed to improve its conversions towards sugar donors. Q327F was the most favorable variant with seven times the conversion enhancement towards UDP-<italic toggle="yes">N</italic>-acetylglucosamine. Likewise, Q327A exhibited 30% conversion enhancement towards UDP-D-xylose. Potent biocatalysts for midecamycin glycosylation were thus obtained through protein engineering. Wild OleD, Q327F and Q327A were used as biocatalysts for scale-up preparation of midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-glucopyranoside, midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-GlcNAc and midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-xylopyranoside. In contrast to midecamycin, these midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-glycosides displayed no antimicrobial activities. These evidences suggested that besides glucosylation, other glycosylation patterns also could inactivate midecamycin, providing a new inactivation mechanism for midecamycin resistance. Cumulatively, glycosylation inactivation of midecamycin was independent of the type of attached sugar moieties at its inactivation site.</p></abstract><kwd-group><kwd>macrolide resistance</kwd><kwd>midecamycin</kwd><kwd>glycodiversification</kwd><kwd>glycosylation inactivation</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-22-12636"><title>1. Introduction</title><p>Antibiotics have been applied extensively in the clinic, veterinary medicine and farming as antibacterials. Of these antibiotics, macrolides are an important group of antibiotics, which account for 20% of all antibiotics prescribed. At least 500 kinds of macrolide antibiotics are known, most of which are derived from <italic toggle="yes">Streptomyces</italic> species. The frequently used macrolide antibiotics are erythromycin [<xref rid="B1-ijms-22-12636" ref-type="bibr">1</xref>], oleandomycin [<xref rid="B2-ijms-22-12636" ref-type="bibr">2</xref>,<xref rid="B3-ijms-22-12636" ref-type="bibr">3</xref>], josamycin [<xref rid="B4-ijms-22-12636" ref-type="bibr">4</xref>,<xref rid="B5-ijms-22-12636" ref-type="bibr">5</xref>], midecamycin [<xref rid="B4-ijms-22-12636" ref-type="bibr">4</xref>,<xref rid="B6-ijms-22-12636" ref-type="bibr">6</xref>], spiramycin [<xref rid="B7-ijms-22-12636" ref-type="bibr">7</xref>,<xref rid="B8-ijms-22-12636" ref-type="bibr">8</xref>], roxithromycin [<xref rid="B9-ijms-22-12636" ref-type="bibr">9</xref>,<xref rid="B10-ijms-22-12636" ref-type="bibr">10</xref>], azithromycin [<xref rid="B11-ijms-22-12636" ref-type="bibr">11</xref>,<xref rid="B12-ijms-22-12636" ref-type="bibr">12</xref>], and clarithromycin [<xref rid="B13-ijms-22-12636" ref-type="bibr">13</xref>,<xref rid="B14-ijms-22-12636" ref-type="bibr">14</xref>]. Macrolides exhibit high activity against Gram-positive bacteria, and are thus used widely as excellent bacteriostatic agents due to their low toxicity and broad-spectrum activities. Macrolide antibiotics inhibit protein synthesis by binding to the nascent peptide exit tunnel of the bacterial ribosome, thus leading to growth arrest or cell death. The action mechanism of macrolides is determined by the location of sugars and specific functional groups on their macrolactone rings [<xref rid="B15-ijms-22-12636" ref-type="bibr">15</xref>,<xref rid="B16-ijms-22-12636" ref-type="bibr">16</xref>,<xref rid="B17-ijms-22-12636" ref-type="bibr">17</xref>]. However, as with other antibiotics, the misuse and overuse of macrolides will inevitably result in antibiotic resistance [<xref rid="B18-ijms-22-12636" ref-type="bibr">18</xref>], which usually causes the decline or loss of antibiotic efficacy. Antibiotic-resistant infections can be difficult and sometimes impossible to treat, thereby resulting in extended hospital stays, higher medical costs and increased mortality. Antibiotic resistance is regarded as one of the biggest threats to healthcare, veterinary and agriculture industries in our time. Hence, it is urgent to explore the underlying mechanisms of macrolide resistance.</p><p>To date, several mechanisms including antibiotics efflux, modifications of the antibiotic targets and antibiotic inactivation have been reported [<xref rid="B19-ijms-22-12636" ref-type="bibr">19</xref>,<xref rid="B20-ijms-22-12636" ref-type="bibr">20</xref>,<xref rid="B21-ijms-22-12636" ref-type="bibr">21</xref>]. Of these mechanisms, antibiotic inactivation is achieved by enzyme-mediated structural modifications, such as phosphorylation, glycosylation and acylation [<xref rid="B19-ijms-22-12636" ref-type="bibr">19</xref>,<xref rid="B20-ijms-22-12636" ref-type="bibr">20</xref>]. Under the actions of modifying enzymes like phosphotransferases (PTs), glycosyltransferases (GTs) and acyltransferases (ATs), macrolide antibiotics are modified to form derivatives with structural alterations, which can impair target binding [<xref rid="B18-ijms-22-12636" ref-type="bibr">18</xref>,<xref rid="B19-ijms-22-12636" ref-type="bibr">19</xref>,<xref rid="B20-ijms-22-12636" ref-type="bibr">20</xref>]. Enzymatic modification of antibiotics has been known as one of the most common resistance mechanisms, which is extensively present in antibiotic producers [<xref rid="B18-ijms-22-12636" ref-type="bibr">18</xref>,<xref rid="B22-ijms-22-12636" ref-type="bibr">22</xref>]. Enzymatic modifications are effective strategies to inactivate antibiotics, thereby avoiding their damage to producers, which is also called self-resistance [<xref rid="B23-ijms-22-12636" ref-type="bibr">23</xref>]. GT-mediated macrolides inactivation has been observed in diverse producers, like <italic toggle="yes">Streptomyces vendargensis</italic> [<xref rid="B24-ijms-22-12636" ref-type="bibr">24</xref>], <italic toggle="yes">S.</italic>
<italic toggle="yes">lividans</italic> [<xref rid="B25-ijms-22-12636" ref-type="bibr">25</xref>,<xref rid="B26-ijms-22-12636" ref-type="bibr">26</xref>,<xref rid="B27-ijms-22-12636" ref-type="bibr">27</xref>], <italic toggle="yes">S.</italic>
<italic toggle="yes">antibioticus</italic> [<xref rid="B28-ijms-22-12636" ref-type="bibr">28</xref>,<xref rid="B29-ijms-22-12636" ref-type="bibr">29</xref>,<xref rid="B30-ijms-22-12636" ref-type="bibr">30</xref>,<xref rid="B31-ijms-22-12636" ref-type="bibr">31</xref>,<xref rid="B32-ijms-22-12636" ref-type="bibr">32</xref>], <italic toggle="yes">Saccharopolyspora erythraea</italic> [<xref rid="B33-ijms-22-12636" ref-type="bibr">33</xref>], Nocardia Species [<xref rid="B34-ijms-22-12636" ref-type="bibr">34</xref>,<xref rid="B35-ijms-22-12636" ref-type="bibr">35</xref>], <italic toggle="yes">S.</italic>
<italic toggle="yes">hygroscopicus</italic> [<xref rid="B36-ijms-22-12636" ref-type="bibr">36</xref>] and <italic toggle="yes">S.ambofaciens</italic> [<xref rid="B37-ijms-22-12636" ref-type="bibr">37</xref>]. Many macrolides, such as erythromycin [<xref rid="B24-ijms-22-12636" ref-type="bibr">24</xref>,<xref rid="B25-ijms-22-12636" ref-type="bibr">25</xref>,<xref rid="B27-ijms-22-12636" ref-type="bibr">27</xref>], tylosin [<xref rid="B25-ijms-22-12636" ref-type="bibr">25</xref>,<xref rid="B27-ijms-22-12636" ref-type="bibr">27</xref>], rosaramicin [<xref rid="B25-ijms-22-12636" ref-type="bibr">25</xref>,<xref rid="B26-ijms-22-12636" ref-type="bibr">26</xref>,<xref rid="B27-ijms-22-12636" ref-type="bibr">27</xref>,<xref rid="B28-ijms-22-12636" ref-type="bibr">28</xref>], chalcomycin [<xref rid="B26-ijms-22-12636" ref-type="bibr">26</xref>,<xref rid="B27-ijms-22-12636" ref-type="bibr">27</xref>], lankamycin [<xref rid="B26-ijms-22-12636" ref-type="bibr">26</xref>,<xref rid="B27-ijms-22-12636" ref-type="bibr">27</xref>,<xref rid="B28-ijms-22-12636" ref-type="bibr">28</xref>], methymycin [<xref rid="B26-ijms-22-12636" ref-type="bibr">26</xref>,<xref rid="B27-ijms-22-12636" ref-type="bibr">27</xref>,<xref rid="B28-ijms-22-12636" ref-type="bibr">28</xref>], pikromycin [<xref rid="B26-ijms-22-12636" ref-type="bibr">26</xref>,<xref rid="B27-ijms-22-12636" ref-type="bibr">27</xref>], oleandomycin [<xref rid="B26-ijms-22-12636" ref-type="bibr">26</xref>,<xref rid="B27-ijms-22-12636" ref-type="bibr">27</xref>,<xref rid="B28-ijms-22-12636" ref-type="bibr">28</xref>,<xref rid="B29-ijms-22-12636" ref-type="bibr">29</xref>], spiramycin [<xref rid="B26-ijms-22-12636" ref-type="bibr">26</xref>,<xref rid="B27-ijms-22-12636" ref-type="bibr">27</xref>], azithromycin [<xref rid="B26-ijms-22-12636" ref-type="bibr">26</xref>,<xref rid="B27-ijms-22-12636" ref-type="bibr">27</xref>] and rapamycin [<xref rid="B38-ijms-22-12636" ref-type="bibr">38</xref>] could be inactivated by glycosylation modifications. The glycosylation inactivation was deemed as a common self-protection mechanism in these macrolide-producing strains.</p><p>Diverse macrolide-inactivating GTs had been isolated and functionally identified. The exemplifying macrolide-inactivating GTs were OleI and OleD from <italic toggle="yes">S. antibioticus</italic> [<xref rid="B31-ijms-22-12636" ref-type="bibr">31</xref>], MGT from <italic toggle="yes">S. lividans</italic> [<xref rid="B25-ijms-22-12636" ref-type="bibr">25</xref>], BaGT from <italic toggle="yes">Bacillus atrophaeus</italic>, BamGT from <italic toggle="yes">B.</italic>
<italic toggle="yes">amyloliquefaciens</italic>, BcGT-1 from <italic toggle="yes">B.cereus</italic>, BgGT from <italic toggle="yes">B.</italic>
<italic toggle="yes">glycinifermentans</italic>, BpGT from <italic toggle="yes">B.</italic>
<italic toggle="yes">paralicheniformis</italic>, as well as BsGT-1 and BssGT from <italic toggle="yes">B.</italic>
<italic toggle="yes">subtilis</italic> [<xref rid="B38-ijms-22-12636" ref-type="bibr">38</xref>,<xref rid="B39-ijms-22-12636" ref-type="bibr">39</xref>]. These GTs have been demonstrated to be acceptor promiscuous, recognizing multiple macrolides. Both OleI and OleD displayed activity against, for example, oleandomycin, carbomycin, tylosin and erythromycin [<xref rid="B31-ijms-22-12636" ref-type="bibr">31</xref>]. MGT could recognize diverse macrolides such as chalcomycin, lankamycin, rosaramicin, methymycin, pikromycin and erythromycin [<xref rid="B25-ijms-22-12636" ref-type="bibr">25</xref>,<xref rid="B26-ijms-22-12636" ref-type="bibr">26</xref>,<xref rid="B27-ijms-22-12636" ref-type="bibr">27</xref>]. Besides acceptor promiscuity, many antibiotic-inactivating GTs like OleI, OleD and MGT showed a wide donor tolerance [<xref rid="B40-ijms-22-12636" ref-type="bibr">40</xref>], attaching diverse sugar moieties to an aglycon through a process named glycodiversification.</p><p>The underlying mechanisms causing macrolide inactivation was elucidated through the structural identification of glycosylated macrolides. MGT usually inactivates methymycin, erythromycin, azithromycin or tylosin through the glucosylation on 2&#x02032;-OH in their mycaminosyl moiety [<xref rid="B25-ijms-22-12636" ref-type="bibr">25</xref>,<xref rid="B26-ijms-22-12636" ref-type="bibr">26</xref>,<xref rid="B27-ijms-22-12636" ref-type="bibr">27</xref>]. Likewise, both OleD and OleI inactivate oleandomycin by 2&#x02032;-glucosylation in the mycaminosyl moiety [<xref rid="B28-ijms-22-12636" ref-type="bibr">28</xref>,<xref rid="B30-ijms-22-12636" ref-type="bibr">30</xref>,<xref rid="B31-ijms-22-12636" ref-type="bibr">31</xref>,<xref rid="B32-ijms-22-12636" ref-type="bibr">32</xref>,<xref rid="B40-ijms-22-12636" ref-type="bibr">40</xref>,<xref rid="B41-ijms-22-12636" ref-type="bibr">41</xref>,<xref rid="B42-ijms-22-12636" ref-type="bibr">42</xref>,<xref rid="B43-ijms-22-12636" ref-type="bibr">43</xref>]. Nocardia species inactivated chalcomycin and tylosin by the glucosylation at 2&#x02032;-OH in the mycaminosyl moiety of the two antibiotics [<xref rid="B35-ijms-22-12636" ref-type="bibr">35</xref>]. In addition, rapamycin inactivation was proved to be caused by glucosylation at its C-28 or C-40 position [<xref rid="B38-ijms-22-12636" ref-type="bibr">38</xref>]. These evidences indicated that glucosylation modification at inactivation sites (C-2&#x02032;, C-28, C-40) was the main glycosylation inactivation pattern of these macrolides. However, the effect of other glycosylation modifications, such as xylosylation and <italic toggle="yes">O</italic>-GlcNAcylation, on macrolide inactivation is still unknown.</p><p>Midecamycin, a naturally occurring 16-membered macrolide, is synthesized from <italic toggle="yes">Streptomyces mycarofaciens</italic> [<xref rid="B44-ijms-22-12636" ref-type="bibr">44</xref>,<xref rid="B45-ijms-22-12636" ref-type="bibr">45</xref>]. It contains a 16-membered lactone ring, to which a disaccharide moiety 4&#x02032;-<italic toggle="yes">O</italic>-(&#x003b1;-L-mycarosyl)-&#x003b2;-D-mycaminosyl is attached [<xref rid="B46-ijms-22-12636" ref-type="bibr">46</xref>]. Midecamycin is active against both erythromycin-susceptible and efflux-mediated erythromycin-resistant strains [<xref rid="B47-ijms-22-12636" ref-type="bibr">47</xref>]. Moreover, midecamycin and its derivatives are also active against mycoplasma species [<xref rid="B4-ijms-22-12636" ref-type="bibr">4</xref>,<xref rid="B6-ijms-22-12636" ref-type="bibr">6</xref>]. Hence, it has been widely applied in the clinic to treat upper and lower respiratory tract infections [<xref rid="B48-ijms-22-12636" ref-type="bibr">48</xref>]. In addition, midecamycin and other macrolides were supplemented in feeds for food-producing animals to treat infectious diseases and promote the health [<xref rid="B49-ijms-22-12636" ref-type="bibr">49</xref>,<xref rid="B50-ijms-22-12636" ref-type="bibr">50</xref>]. Due to the important roles in clinical therapy and animal-derived food safety, midecamycin resistance has attracted significant attention [<xref rid="B34-ijms-22-12636" ref-type="bibr">34</xref>,<xref rid="B35-ijms-22-12636" ref-type="bibr">35</xref>]. Midecamycin resistance was due to drug inactivation caused by phosphorylation, reduction, deacylation, or a combination thereof [<xref rid="B34-ijms-22-12636" ref-type="bibr">34</xref>,<xref rid="B35-ijms-22-12636" ref-type="bibr">35</xref>]. It was not clear, however, that the glycosylation modifications including glucosylation of midecamycin could inactivate midecamycin.</p><p>Herein, midecamycin inactivation caused by varied glycosylation modifications was demonstrated. Specifically, OleD was screened from four candidate GTs as the most favorable biocatalyst to glycodiversify midecamycin, generating five 2&#x02032;-substituted glycosides, most of which had low yields (<xref rid="ijms-22-12636-f001" ref-type="fig">Figure 1</xref>). Protein engineering was then conducted with the aim to improve the conversions of OleD towards five reactive donors. Q327F and Q327A were thus identified as the most favorable biocatalysts capable of increasing the conversion towards UDP-GlcNAc and UDP-Xyl, respectively. OleD, Q327F and Q327A were thus used as the biocatalysts for scale preparation of midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-glucopyranoside, midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-acetylglucosamine and midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-xylopyranoside, respectively. The antimicrobial activities of the three midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-glycosides were lost completely. These data indicated that glycosylation inactivation could contribute to midecamycin resistance. Besides glucosylation, other glycosylation patterns could result in midecamycin inactivation, suggesting glycosylation inactivation of midecamycin was independent of the type of attached sugar moieties. This study will lay a foundation for the mechanism clarification of macrolide resistance and the development of GT inhibitors as drugs.</p></sec><sec sec-type="results" id="sec2-ijms-22-12636"><title>2. Results</title><sec id="sec2dot1-ijms-22-12636"><title>2.1. Expression and Purification of GTs</title><p>OleD [<xref rid="B41-ijms-22-12636" ref-type="bibr">41</xref>], DesVII [<xref rid="B51-ijms-22-12636" ref-type="bibr">51</xref>], SpnP [<xref rid="B52-ijms-22-12636" ref-type="bibr">52</xref>,<xref rid="B53-ijms-22-12636" ref-type="bibr">53</xref>] and Srm29 [<xref rid="B54-ijms-22-12636" ref-type="bibr">54</xref>] are macrolide GTs. Hence, these GTs were selected as the candidate biocatalysts for glycosylation of midecamycin. The genes encoding the four GTs were thus induced to express in <italic toggle="yes">Escherichia coli</italic> for preparative production of biocatalysts, respectively. SDS-PAGE analysis showed that an intense band with the expected size of 45.7 kDa was present in the supernatant of the recombinant strain harboring <italic toggle="yes">OleD</italic> gene. On the contrary, no corresponding band was detected in the control supernatant, suggesting <italic toggle="yes">OleD</italic> was successfully expressed in <italic toggle="yes">E. coli</italic> as a soluble product. The soluble OleD protein was subsequently purified to near homogeneity, reaching 107.96 mg/mL (<xref rid="ijms-22-12636-f002" ref-type="fig">Figure 2</xref>A). Likewise, the other three genes <italic toggle="yes">desVII</italic>, <italic toggle="yes">spnP</italic> and <italic toggle="yes">srm29</italic> were demonstrated to be expressed as soluble forms in <italic toggle="yes">E. coli</italic> (<xref rid="app1-ijms-22-12636" ref-type="app">Figure S1</xref>). The concentration of the purified DesVII, SpnP and Srm29 was 40.32, 50.83 and 46.67 mg/mL, respectively. These recombinant GTs were then used as the biocatalysts to glucosylate midecamycin.</p></sec><sec id="sec2dot2-ijms-22-12636"><title>2.2. Glucosylation of Midecamycin</title><p>Each of these purified OleD, DesVII, SpnP and Srm29 was used as the biocatalyst to react with UDP-Glc and midecamycin, respectively. Results indicated that four GTs could glucosylate midecamycin to form new products (<xref rid="ijms-22-12636-f002" ref-type="fig">Figure 2</xref>B). Of the four GTs, OleD exhibited the most favorable glucosylating activity towards midecamycin. OleD could glucosylate midecamycin to yield two products 1a and 1b (<xref rid="ijms-22-12636-f002" ref-type="fig">Figure 2</xref>B). Conversely, the other three GTs could glucosylate midecamycin to form trace products (<xref rid="ijms-22-12636-f002" ref-type="fig">Figure 2</xref>B). Hence, the purified OleD was used as the biocatalyst for further glycodiversification of midecamycin.</p><p>The newly formed peaks 1a and 1b displayed similar UV spectra with that of midecamycin (<xref rid="ijms-22-12636-f002" ref-type="fig">Figure 2</xref>C), suggesting the two products containing similar skeleton structure with that of midecamycin. The newly formed 1a and 1b exhibited [M + H]<sup>+</sup> ion peaks with <italic toggle="yes">m/z</italic> values of 976.5081 (<xref rid="ijms-22-12636-f002" ref-type="fig">Figure 2</xref>D) and 976.5082 (<xref rid="ijms-22-12636-f002" ref-type="fig">Figure 2</xref>E), respectively, which revealed both were monoglucosylated products of midecamycin with <italic toggle="yes">m/z</italic> value of 814.4577 (<xref rid="ijms-22-12636-f002" ref-type="fig">Figure 2</xref>F). The compound 1a was collected and then analyzed by NMR measurement. <sup>1</sup>H and <sup>13</sup>C-NMR data assigned 1a as midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-glucopyranoside (<xref rid="ijms-22-12636-t001" ref-type="table">Table 1</xref>, <xref rid="app1-ijms-22-12636" ref-type="app">Figures S2&#x02013;S6</xref>), suggesting OleD preferred to attack 2&#x02032;-OH in mycaminosyl moiety of midecamycin. In addition, OleD was able to glucosylate 2&#x02032;-OH of oleandomycin [<xref rid="B25-ijms-22-12636" ref-type="bibr">25</xref>,<xref rid="B26-ijms-22-12636" ref-type="bibr">26</xref>,<xref rid="B27-ijms-22-12636" ref-type="bibr">27</xref>,<xref rid="B28-ijms-22-12636" ref-type="bibr">28</xref>,<xref rid="B38-ijms-22-12636" ref-type="bibr">38</xref>,<xref rid="B39-ijms-22-12636" ref-type="bibr">39</xref>,<xref rid="B40-ijms-22-12636" ref-type="bibr">40</xref>]. These facts collectively indicated that 2&#x02032;-OH might be the preferred site of glycosylation for macrolides. In an attempt to collect 1b for structural identification, this compound was found to be unstable and could be easily converted to 1a. It was speculated that there was an isomerization between 1a and 1b, which resulted from the allylic rearrangement caused by two conjugated double bonds in midecamycin. The isomerization of the diene alcohol system in macrolides had been observed previously [<xref rid="B55-ijms-22-12636" ref-type="bibr">55</xref>,<xref rid="B56-ijms-22-12636" ref-type="bibr">56</xref>]. The instability of 1b, together with its trace amount in the reaction mixture, made it was difficult to purify 1b. Hence, the exact structure of 1b had not been assigned.</p><p>The effect of pH and temperature on OleD-catalyzed glucosylation towards midecamycin was illustrated in <xref rid="app1-ijms-22-12636" ref-type="app">Figure S7</xref>. OleD exhibited a wide pH tolerance ranging from pH 4.0 to pH 12.0. When pH was between 9 and 10, the highest OleD activity was observable. Likewise, OleD had a wide range of temperature tolerance. It kept activity from 0 to 70 &#x000b0;C and got the highest activity at 50 &#x000b0;C. When the temperature was 70 &#x000b0;C, the residual activity of OleD was more than 25%. Hence, the optimal pH 9.0 and optimal temperature 50 &#x000b0;C were determined as the reaction conditions in the following assays unless otherwise specified. The kinetic parameters were determined under the optimal reaction conditions and summarized in <xref rid="ijms-22-12636-t002" ref-type="table">Table 2</xref>.</p></sec><sec id="sec2dot3-ijms-22-12636"><title>2.3. OleD-Mediated Glycodiversificaion of Midecamycin</title><p>The glycodiversification capacity of OleD towards midecamycin was explored with the aim to enzymatically synthesize an array of midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-glycosides. Each of the compounds summarized in <xref rid="app1-ijms-22-12636" ref-type="app">Figure S8</xref> was used as the sugar donor to react with midecamycin under the action of OleD (<xref rid="ijms-22-12636-f003" ref-type="fig">Figure 3</xref>). OleD was reactive with five donors, including UDP-Glc, UDP-Xyl, UDP-Gal, UDP-Rha and UDP-GlcNAc, but stringently repellent to UDP-glucuronic acid (UDP-GlcA), UDP-<italic toggle="yes">N</italic>-acetylgalactosamine (UDP-GalNAc), GDP-mannose (GDP-Man) and other donors in <xref rid="app1-ijms-22-12636" ref-type="app">Figure S8</xref>. Like UDP-Glc, UDP-Xyl reacted with midecamycin to form two products 1c and 1d displaying similar UV spectra with that of midecamycin (<xref rid="ijms-22-12636-f003" ref-type="fig">Figure 3</xref>A,E). Mass analyses of the two peaks showed <italic toggle="yes">m/z</italic> ions of 946.4995 and 946.4982, respectively, suggesting 1c and 1d were monoxylosylated products of midecamycin (<xref rid="ijms-22-12636-f003" ref-type="fig">Figure 3</xref>C,D). Further NMR analysis assigned 1c as midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-xylopyranoside (<xref rid="ijms-22-12636-t001" ref-type="table">Table 1</xref>, <xref rid="app1-ijms-22-12636" ref-type="app">Figures S9&#x02013;S13</xref>). The midecamycin xyloside 1d was also unstable, and might be an allylic isomer of 1c (<xref rid="ijms-22-12636-f003" ref-type="fig">Figure 3</xref>A). Moreover, the yield of 1d was very low. Therefore, we did not identify the structure of 1d.</p><p>The other three donors, UDP-Gal, UDP-Rha and UDP-GlcNAc, could react with midecamycin to yield one product, respectively (<xref rid="ijms-22-12636-f003" ref-type="fig">Figure 3</xref>A). HRESIMS demonstrated their monoglycosylated products of midecamycin (<xref rid="app1-ijms-22-12636" ref-type="app">Figure S14</xref>). According to the catalytic behavior of OleD towards midecamycin, these glycosylated midecamycin derivatives 1e, 1f and 1g could reasonably deduced to midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-galactopyranoside (1e), midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-rhamnoside (1f) and midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-acetylglucosamine (1g) (<xref rid="ijms-22-12636-f003" ref-type="fig">Figure 3</xref>). However, more evidences are still needed to determine the exact structure of these monoglycosides. Hence, OleD was demonstrated to glycodiversify midecamycin, attaching five sugar moieties including glucosyl, xylosyl, galactosyl, rhamnosyl and <italic toggle="yes">N</italic>-acetylglucosamine (GlcNAc) at 2&#x02032;-OH, respectively (<xref rid="ijms-22-12636-f003" ref-type="fig">Figure 3</xref>A). OleD displayed distinct catalytic efficiencies towards these donors (<xref rid="ijms-22-12636-f003" ref-type="fig">Figure 3</xref>B). The conversion of UDP-Glc was the highest, approaching to 91.3%. OleD had low catalytic efficiency for other four donors. The conversion of UDP-Xyl was only 27%, while those of UDP-Gal, UDP-Rha and UDP-GlcNAc were lower, giving 3.96%, 7.62%, 4.56%, respectively (<xref rid="ijms-22-12636-f003" ref-type="fig">Figure 3</xref>B). It was difficult to collect enough amounts of glycosylated products 1c, 1e, 1f and 1g for activity evaluation due to the low conversions. Hence, protein engineering of OleD based on homology modeling was performed with the aim to improve its catalytic efficiency towards UDP-Xyl, UDP-Gal, UDP-Rha or UDP-GlcNAc.</p><p>GlcNAc and 2-deoxy-2-fluoroglucose are derivatives of glucose. Moreover, the complex of UGT72B1 (a GT displaying similar structure with that of OleD) and UDP-2-deoxy-2-fluoroglucose (U2F) could provide a reference for homology modeling of OleD with UDP-GlcNAc [<xref rid="B57-ijms-22-12636" ref-type="bibr">57</xref>]. Hence, we put the emphasis on the enhancement of the conversion of OleD towards UDP-GlcNAc.</p></sec><sec id="sec2dot4-ijms-22-12636"><title>2.4. Protein Engineering of OleD to Enhance Its Catalytic Efficiencies</title><p>The complex of OleD with U2F was obtained through the alignment and superposition with wild type OleD (PDB ID: 2IYF) and UGT72B1 (PDB ID: 2VCE). Next, the fluoride ion at C-2 of glucose moiety in U2F was replaced with <italic toggle="yes">N</italic>-acetyl group to yield a complex of OleD with UDP-GlcNAc. As observed from the modelled complex structure of OleD with UDP-GlcNAc, the residue Gln331 in OleD formed hydrogen bond with the O3 of GlcNAc, suggesting the critical interaction of a sugar donor with OleD (<xref rid="app1-ijms-22-12636" ref-type="app">Figure S15</xref>). Gln331 was a component of the strictly conserved signature Glu/Asp-Gln (E/D-Q) and no mutations were therefore performed on this residue [<xref rid="B41-ijms-22-12636" ref-type="bibr">41</xref>,<xref rid="B57-ijms-22-12636" ref-type="bibr">57</xref>,<xref rid="B58-ijms-22-12636" ref-type="bibr">58</xref>]. We focused on amino acids less than 5&#x000c5; away from Gln331, such as Gln327, Val329, Asp330 and Phe332, which might affect the binding of Gln331 to glycosyl donors (<xref rid="app1-ijms-22-12636" ref-type="app">Figure S15</xref>). Alanine-scanning mutagenesis of these four residues was thus performed. Four alanine mutants of OleD, namely Q327A, V329A, D330A and F332A, were yielded and their catalytic activities towards UDP-GlcNAc, UDP-Xyl, UDP-Gal, UDP-Rha and UDP-Glc were measured. Q327A variant displayed an improved activity towards UDP-GlcNAc. Conversely, the catalytic activity of the mutant D330A towards the five donors was lost completely. Hence, the residue Q327 was selected for further saturation mutagenesis (<xref rid="app1-ijms-22-12636" ref-type="app">Figure S16</xref>).</p><p>Saturation mutation on Q327 was performed and 19 recombinant OleD mutants were thus induced to express in <italic toggle="yes">E. coli</italic> (<xref rid="app1-ijms-22-12636" ref-type="app">Figure S17</xref>). Each of these crude mutants was used as the biocatalyst to incubate with midecamycin and UDP-GlcNAc, UDP-Xyl or UDP-Glc, respectively. As illustrated in <xref rid="app1-ijms-22-12636" ref-type="app">Figure S18C</xref>, the UDP-GlcNAc conversions of 16 mutants increased while the other three mutants, Q327D, Q327E and Q327P, decreased. The most notable increase in UDP-GlcNAc conversion occurred in Q327F mutant. The UDP-GlcNAc conversion of Q327F reached 30.7%, eight times higher than that of the wild OleD (3.6%).</p><p>The UDP-Xyl conversion of these variants was also measured (<xref rid="app1-ijms-22-12636" ref-type="app">Figure S18B</xref>). The conversion of 12 variants towards UDP-Xyl increased, while the other seven obtained a decreased conversion towards UDP-Xyl. The conversion of Q327D and Q327P towards UDP-Xyl decreased significantly. Specifically, the conversion of Q327D declined below 5% while the catalytic activity of Q327P was lost completely. Of 12 mutants with increased activity, Q327I obtained the highest conversion of 46.5% towards UDP-Xyl (<xref rid="app1-ijms-22-12636" ref-type="app">Figure S18B</xref>), 33% more than that of wild OleD (34.9%).</p><p>In addition, the conversion of these variants towards UDP-Glc was also determined (<xref rid="app1-ijms-22-12636" ref-type="app">Figure S18A</xref>). Of these 19 variants, the conversion of Q327D towards UDP-Glc decreased to 50%, while the catalytic efficiency of Q327P towards UDP-Glc was lost completely. The other 17 mutations at Q327 residue led to an insignificant variation of OleD activity towards UDP-Glc (<xref rid="app1-ijms-22-12636" ref-type="app">Figure S18A</xref>). Cumulatively, Q327 residue was a favorable site to improve the conversions towards UDP-GlcNAc. The saturation mutations at Q327, however, did not improve the conversion significantly towards UDP-Xyl and UDP-Glc. Thus, the measurement of more residues is required so as to obtain favorable variants with improved conversions towards UDP-Xyl and UDP-Glc. Considering that saturation mutation of Q327 could only significantly increase the conversion towards UDP-GlcNAc, the effects of saturation mutation of Q327 on the conversions towards UDP-Gal and UDP-Rha were thus not tested.</p><p>In order to further verify these results, five Q327 mutants ranking first to fifth in UDP-GlcNAc conversion were purified (<xref rid="ijms-22-12636-f004" ref-type="fig">Figure 4</xref>A). The concentrations of these purified enzymes were 62.03 (Q327F), 82.52 (Q327H), 99.57 (Q327M), 67.26 (Q327R) and 89.91 mg/mL (Q327W), respectively, and were used as biocatalysts to react with midecamycin and UDP-GlcNAc (<xref rid="ijms-22-12636-f004" ref-type="fig">Figure 4</xref>B). The conversions of these mutants towards UDP-GlcNAc increased significantly. The highest conversion occurred on Q327F variant, reaching 34.13 &#x000b1; 1.55% (<xref rid="ijms-22-12636-f004" ref-type="fig">Figure 4</xref>).</p><p>The wild type OleD and its variants Q327I and Q327F were used as the biocatalysts for scale preparation of midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-glucopyranoside, midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-xylopyranoside, and midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-acetylglucosamine, respectively. These enzymatically synthesized midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-glycosides were then used to test their water solubility and biological activities.</p></sec><sec id="sec2dot5-ijms-22-12636"><title>2.5. Water Solubility of Midecamycin 2&#x02032;-O-Glucopyranoside</title><p>Glycosylation modifications usually increase the water solubility of compounds. This notion was further confirmed by the fact that the water solubility of midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-glucopyranoside was greater than that of midecamycin. The water solubility of the enzymatically synthesized midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-glucopyranoside was 8.62 mg/mL, 11 times higher than that of midecamycin (0.74 mg/mL).</p></sec><sec id="sec2dot6-ijms-22-12636"><title>2.6. Antimicrobial Activities of Midecamycin 2&#x02032;-O-Glycosides</title><p>As shown in <xref rid="ijms-22-12636-t003" ref-type="table">Table 3</xref>, the MIC values of midecamycin against <italic toggle="yes">Bacillus intestinalis</italic> strain T30, <italic toggle="yes">B.</italic>
<italic toggle="yes">subtilis</italic> strain 168, <italic toggle="yes">Staphylococcus aureus</italic> and <italic toggle="yes">Streptococcus pneumoniae</italic> were 0.5, 1, 1 and 0.25 &#x003bc;g/mL, respectively, suggesting midecamycin exhibited potent antibacterial activities. Three midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-glycosides, however, displayed no antibacterial activities against the tested microorganisms listed in <xref rid="ijms-22-12636-t003" ref-type="table">Table 3</xref>, even if the maximum concentration of these glycosides reached 64 &#x003bc;g/mL. The midecamycin inactivation caused by glycosylation might be due to the configuration change of midecamycin, which in turn prevented the binding of midecamycin to its target [<xref rid="B41-ijms-22-12636" ref-type="bibr">41</xref>]. More evidences are required to analyze the exact mechanism underlying the resistance to midecamycin by glycosylation.</p></sec></sec><sec sec-type="discussion" id="sec3-ijms-22-12636"><title>3. Discussion</title><p>Antibiotic resistance is one of the biggest threats to human health and food security. The infections of humans or animals caused by antibiotic-resistant bacteria will increase mortality and medical costs. Understanding more about the resistance mechanisms will be helpful for better treatment of infections caused by antibiotic-resistant bacteria. Glucosylation inactivation is one of the important resistance mechanisms [<xref rid="B24-ijms-22-12636" ref-type="bibr">24</xref>,<xref rid="B25-ijms-22-12636" ref-type="bibr">25</xref>,<xref rid="B26-ijms-22-12636" ref-type="bibr">26</xref>,<xref rid="B27-ijms-22-12636" ref-type="bibr">27</xref>,<xref rid="B28-ijms-22-12636" ref-type="bibr">28</xref>,<xref rid="B29-ijms-22-12636" ref-type="bibr">29</xref>,<xref rid="B30-ijms-22-12636" ref-type="bibr">30</xref>,<xref rid="B31-ijms-22-12636" ref-type="bibr">31</xref>,<xref rid="B32-ijms-22-12636" ref-type="bibr">32</xref>,<xref rid="B33-ijms-22-12636" ref-type="bibr">33</xref>,<xref rid="B34-ijms-22-12636" ref-type="bibr">34</xref>,<xref rid="B35-ijms-22-12636" ref-type="bibr">35</xref>,<xref rid="B36-ijms-22-12636" ref-type="bibr">36</xref>,<xref rid="B37-ijms-22-12636" ref-type="bibr">37</xref>]. However, if other glycosylation modifications will inactivate antibiotics is not clear. Herein, we took macrolide antibiotic midecamycin as the research object and demonstrated that besides glucosylation, other glycosylation modifications could cause antibiotics inactivation for the first time.</p><p>This work has at least three contributions to the new cognition in this field. First, this study provided a novel mechanism for midecamycin inactivation. Midecamycin is an important macrolide antibiotic. The research on its inactivation mechanism contributed to the comprehensive understanding of macrolide resistance. In this manuscript, we convincingly demonstrated glycosylation inactivation was a novel mechanism of midecamycin resistance, which broadened the understanding of midecamycin resistance.</p><p>Second, we demonstrated that glycosylation inactivation of midecamycin was independent of the type of attached sugar moieties at its inactivation site. Varied glycosylation modifications, including glucosylation, xylosylation and <italic toggle="yes">O</italic>-GlcNAcylation, could inactivate midecamycin, suggesting varied glycosylation modifications at the same inactivation site could lead to antibiotic resistance.</p><p>Finally, <italic toggle="yes">O</italic>-GlcNAcylation improvement of midecamycin was achieved in this investigation. The wild OleD displayed a low <italic toggle="yes">O</italic>-GlcNAcylation efficiency towards midecamycin, which limited the scale preparation of midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-acetylglucosamine. The protein engineering was performed to enhance the <italic toggle="yes">O</italic>-GlcNAcylation efficiency of OleD. The residue Q327 was identified as the key amino acid regulating <italic toggle="yes">O</italic>-GlcNAcylation of OleD. Q327F was determined as the most favorable OleD variant with seven times conversion enhancement towards UDP-GlcNAc. These data provided a reference for activity improvement of other modifying enzymes.</p><p>The facts convincingly demonstrated that varied glycosylation modifications, including glucosylation, xylosylation and <italic toggle="yes">O</italic>-GlcNAcylation could inactivate midecamycin. Besides glycosylation modifications, the resistance to midecamycin could also be achieved by the combinational modification of phosphorylation of 2&#x02032;-OH and reduction at the 18-formyl group (18-dihydro-2&#x02032;-<italic toggle="yes">O</italic>-phosphorylmidecamycin) [<xref rid="B34-ijms-22-12636" ref-type="bibr">34</xref>,<xref rid="B35-ijms-22-12636" ref-type="bibr">35</xref>]. These evidences suggest that multiple modifications at 2&#x02032;-OH can cause midecamycin inactivation. Hence, 2&#x02032;-OH is a key determinator for midecamycin activity. 2&#x02032;-OH of the desosamine moiety, which locates at C5 position of midecamycin and some macrolides, can make specific hydrogen bond interaction with the nucleobase of A2058 of the 23S rRNA, thereby facilitating the occupation of macrolide drugs in the nascent peptide exit tunnel. The glycosylation at 2&#x02032;-OH might blocked the binding between the desosamine hydroxyl and the N1 atom of A2058, thus leading to macrolide resistance [<xref rid="B18-ijms-22-12636" ref-type="bibr">18</xref>,<xref rid="B59-ijms-22-12636" ref-type="bibr">59</xref>]. We demonstrated the glycosylation inactivation occurred in midecamycin herein. Still, more evidences are required to determine the exact action mechanism of glycosylation inactivation.</p><p>Glycosylation inactivation had been explored comprehensively in <italic toggle="yes">S.</italic>
<italic toggle="yes">antibioticus</italic>, the producer of the well-known macrolide oleandomycin [<xref rid="B28-ijms-22-12636" ref-type="bibr">28</xref>,<xref rid="B29-ijms-22-12636" ref-type="bibr">29</xref>,<xref rid="B30-ijms-22-12636" ref-type="bibr">30</xref>,<xref rid="B31-ijms-22-12636" ref-type="bibr">31</xref>,<xref rid="B43-ijms-22-12636" ref-type="bibr">43</xref>]. An array of GTs capable of glycosylating macrolides had been identified, suggesting macrolide-inactivating GTs might exist extensively in antibiotic-producing organisms [<xref rid="B28-ijms-22-12636" ref-type="bibr">28</xref>,<xref rid="B29-ijms-22-12636" ref-type="bibr">29</xref>,<xref rid="B30-ijms-22-12636" ref-type="bibr">30</xref>,<xref rid="B31-ijms-22-12636" ref-type="bibr">31</xref>,<xref rid="B43-ijms-22-12636" ref-type="bibr">43</xref>,<xref rid="B51-ijms-22-12636" ref-type="bibr">51</xref>,<xref rid="B52-ijms-22-12636" ref-type="bibr">52</xref>,<xref rid="B53-ijms-22-12636" ref-type="bibr">53</xref>,<xref rid="B60-ijms-22-12636" ref-type="bibr">60</xref>]. An OleD isoenzyme might exist in the midecamycin-producing species <italic toggle="yes">S. mycarofaciens</italic> [<xref rid="B61-ijms-22-12636" ref-type="bibr">61</xref>]. Further study on this glycosyltransferase will help to understand the inactivation mechanism of midecamycin glycosylation. Cumulatively, this investigation will thus lay a foundation for the mechanism clarification of macrolide resistance and the development of GT inhibitors as drugs.</p></sec><sec id="sec4-ijms-22-12636"><title>4. Materials and Methods</title><sec id="sec4dot1-ijms-22-12636"><title>4.1. Chemicals</title><p>Midecamycin (1) was purchased from Yuanye Bio-Technology Co., Ltd. (Shanghai, China). The compounds listed in <xref rid="app1-ijms-22-12636" ref-type="app">Figure S8</xref> were used as glycosyl donors for glycosylation reactions. These donors were obtained from Sigma-Aldrich Co. LLC (St. Louis, MO, USA), Yuanye Bio-Technology Co., Ltd., J&#x00026;K Scientific Ltd. (Beijing, China), and Qiyue Biological Technology Co.,Ltd (Xi&#x02019;an, China), respectively. Acetonitrile and methanol were obtained from MREDA (Beijing, China). Other chemicals and reagents were of analytical grade.</p></sec><sec id="sec4dot2-ijms-22-12636"><title>4.2. Plasmids and Strains</title><p>The <italic toggle="yes">E. coli</italic> strains <italic toggle="yes">Trans</italic>1-T1 and BL21 (DE3) (TransGen Biotech, Beijing, China) were used as the hosts for the plasmid amplification and heterologous expression, respectively. The genes encoding DesVII (accession No. AAC68677.1) [<xref rid="B62-ijms-22-12636" ref-type="bibr">62</xref>], OleD (accession No. WP_063854495.1) [<xref rid="B40-ijms-22-12636" ref-type="bibr">40</xref>], SpnP (accession NO. AAG23277.1) [<xref rid="B63-ijms-22-12636" ref-type="bibr">63</xref>] and Srm29 (accession No. QBG49784.1) [<xref rid="B7-ijms-22-12636" ref-type="bibr">7</xref>] were synthesized in Taihe Biotechnology (Beijing, China). The synthetic oleD gene was inserted between <italic toggle="yes">Bam</italic>H &#x02160; and <italic toggle="yes">Eco</italic>R &#x02160; sites of pET-His (<xref rid="app1-ijms-22-12636" ref-type="app">Figure S19</xref>), while the other three genes were cloned into pColdTF (Takara Bio (Dalian) Co. Ltd., Dalian, China) at the <italic toggle="yes">Xho</italic> &#x02160; and <italic toggle="yes">Hin</italic>d &#x02162; sites to obtain their respective expression vectors (<xref rid="app1-ijms-22-12636" ref-type="app">Table S1</xref>). The recombinant plasmids were constructed using seamless assembly cloning kit (CloneSmarter Technologies Inc., Houston, TX, USA). The primers used in plasmids construction were listed in <xref rid="app1-ijms-22-12636" ref-type="app">Table S2</xref>. The authenticity of these recombinant plasmids was verified by direct sequencing.</p></sec><sec id="sec4dot3-ijms-22-12636"><title>4.3. Protein Expression and Purification</title><p>A single colony containing an expression plasmid was grown in 10 mL LB medium supplemented with a final concentration of 0.1 mg/mL ampicillin at 37 &#x000b0;C for 6&#x02013;8 h. Next, 3 mL cultures were removed and transferred into 300 mL fresh LB medium containing appropriate ampicillin for large-scale cultivation. When the OD<sub>600</sub> of the cultures reached 0.6&#x02013;0.8, isopropyl-&#x003b2;-D-thiogalactopyranoside (IPTG) was added with a final concentration of 0.2 mM to induce expression of pETHis-OleD. As for pColdTF-derived plasmids, there was a 30-min rest period at 15 &#x000b0;C prior to 0.2 mM IPTG induction. The cultures continued to grow at 18 &#x000b0;C for additional 20 h after IPTG addition. The cell pellets were collected by centrifugation at 10,625&#x000d7; <italic toggle="yes">g</italic> and resuspended in PBS buffer (20 mM, pH 8.0). The cells were sonicated, and the supernatant was collected by centrifugation at 10,625&#x000d7; <italic toggle="yes">g</italic> and 4 &#x000b0;C for 2 min. The protein expressions were analyzed by the sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), and purified using Ni-Agarose Resin (CoWin Biotech Co., Ltd., Beijing, China). The concentration of the purified proteins was determined using Nano-300 Micro-Spectrophotometer (Hangzhou Allsheng Instruments Co., Ltd., Zhejiang, China).</p></sec><sec id="sec4dot4-ijms-22-12636"><title>4.4. Glycosylation Assays</title><p>The glycosylation assays were performed in 100 &#x000b5;L PBS buffer (20 mM, pH 8.0) containing 1 mM sugar donor, 1 mM midecamycin (dissolved in DMSO) and 200 &#x003bc;g of a purified GT. After incubated at 37 &#x000b0;C for 2 h, the reactions were terminated by adding the equal volume of methanol and 5 &#x003bc;L glacial acetic acid. The reaction mixtures were separated by centrifugation at 10,625&#x000d7; <italic toggle="yes">g</italic> for 10 min. The resultant supernatants were filtered through 0.22 &#x000b5;m filter and directly monitored by HPLC and HPLC-MS with a C18 column (SilGreen C18, 250 mm &#x000d7; 4.6 mm, 5 &#x003bc;m). The mobile phase consisted of solvent A (10 mM ammonium acetate, pH 8.0) and solvent B (acetonitrile, HPLC grade), with a flow rate of 1.0 mL/min for 35 min. The concentration of solvent B was 10&#x02013;90% (from 0 to 35 min). The conversion rate (%) was calculated by dividing the peak area of the glycosylation product by the sum of the peak areas of the product and the remaining substrate. The high resolution electrospray ionization mass spectroscopy (HR-ESI-MS) and nuclear magnetic resonance (NMR) data were recorded as described previously [<xref rid="B64-ijms-22-12636" ref-type="bibr">64</xref>].</p></sec><sec id="sec4dot5-ijms-22-12636"><title>4.5. Condition Optimization for OleD-Catalyzed Reactions</title><p>The effects of pH and temperature on OleD-catalyzed glucosylation towards midecamycin were explored. The pH dependence of OleD-catalyzed glucosylation was tested in varied buffers including citric acid/sodium citrate buffer (10 mM, pH 3.0&#x02013;5.6), PBS buffer (20 mM, pH 7.0&#x02013;8.0) and Na<sub>2</sub>CO<sub>3</sub>-NaHCO<sub>3</sub> buffer (10 mM, pH 9.0&#x02013;12.0). All reactions were incubated at 37 &#x000b0;C for 2 h.</p><p>The effect of temperature was measured on the optimal optimum Na<sub>2</sub>CO<sub>3</sub>-NaHCO<sub>3</sub> buffer (10 mM, pH 9.0). Reactions were measured at different temperatures (0, 10, 20, 30, 37, 50, 60, 70 &#x000b0;C) for 2 h.</p><p>Kinetic characteristics were tested under the optimal pH and temperature, using different concentrations of midecamycin (0.002&#x02013;2 mM) and UDP-Glc (0.004&#x02013;4 mM). Non-linear regression calculations were used to directly determine the apparent kinetic parameters (<italic toggle="yes">K</italic><sub>m</sub> and V<sub>max</sub>) by GraphPad Prism 7.0.</p></sec><sec id="sec4dot6-ijms-22-12636"><title>4.6. Molecular Docking of Ligands with Proteins</title><p>Molecular docking of OleD with UDP-GlcNAc was performed using the same procedures as described by Gantt et al. [<xref rid="B57-ijms-22-12636" ref-type="bibr">57</xref>].</p></sec><sec id="sec4dot7-ijms-22-12636"><title>4.7. Directed Mutations of OleD</title><p>Using pETHis-OleD plasmid as the template, the directed mutation of OleD was performed in the 2&#x000d7;<italic toggle="yes">TransStart</italic><sup>&#x000ae;</sup>
<italic toggle="yes">FastPfu</italic> RCR SuperMix according to the direction of the manufacturer (TransGen Biotech.). The primers for OleD mutations were summarized in the supporting <xref rid="app1-ijms-22-12636" ref-type="app">Table S2</xref>. Cloning mutant products were verified using sanger sequencing. The procedures for protein expression, purification, and glycosylation assays were the same as mentioned above.</p></sec><sec id="sec4dot8-ijms-22-12636"><title>4.8. Water Solubility Assay</title><p>The water solubility of midecamycin and midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-glucopyranoside was detected using miniaturized shake-flask solubility method [<xref rid="B65-ijms-22-12636" ref-type="bibr">65</xref>]. Specifically, midecamycin and midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-glucopyranoside were added into 100 &#x003bc;L ddH<sub>2</sub>O until turbidity appeared, respectively. After ultrasonic treatment for 30 min, the two mixtures were allowed to stand at room temperature for 3 h. Next, the mixtures were separated by the centrifugation at 10,625&#x000d7; <italic toggle="yes">g</italic> for 30 min, and the resulting supernatants were filtered with 0.22 &#x003bc;M filter membrane. The concentration of filtrate is determined by HPLC.</p></sec><sec id="sec4dot9-ijms-22-12636"><title>4.9. Evaluation of Antimicrobial Activity of Midecamycin 2&#x02032;-O-Glycosides</title><p>The determination of antimicrobial activity of midecamycin and its glycosides were based on their minimum inhibitory concentrations (MICs) against the tested microorganisms. The MICs of midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-glycosides were measured using the broth microdilution procedure described previously [<xref rid="B66-ijms-22-12636" ref-type="bibr">66</xref>]. Briefly, the cell suspensions of these tested microorganisms were prepared from a 24 h-culture using LB liquid medium (BHI medium for <italic toggle="yes">S. pneumoniae</italic>). The serial dilutions of midecamycin and its glycosides were made using the corresponding mediums in serially decreasing concentrations from 64 &#x003bc;g/mL. The same amount of diluent and bacterial solution (usually 200 &#x003bc;L each) were added to 96 well plate and incubated at 37 &#x000b0;C overnight. The OD<sub>600</sub> of each well was recorded and the lowest concentration that inhibited bacterial growth completely was defined as MIC values of midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-glycosides.</p></sec></sec><sec sec-type="conclusions" id="sec5-ijms-22-12636"><title>5. Conclusions</title><p>Glucosylation inactivation is one of commonly-accepted resistance mechanisms on antibiotics. Still, the effect of other glycosylation modifications, such as xylosylation and <italic toggle="yes">O</italic>-GlcNAcylation, on macrolide inactivation is unclear. Herein, we demonstrated that besides glucosylation inactivation, other glycosylation could inactivate macrolide antibiotics, deepening the understanding on glycosylation inactivation of antibiotics. In addition, glycosylation modification has been proved to be a new mechanism of midecamycin resistance. Moreover, glycosylation inactivation of midecamycin was independent of the type of attached sugar moieties at its inactivation site. These data contribute to the in-depth understanding of the resistance mechanism and lay a foundation for the development of glycosyltransferase inhibitors.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><app-group><app id="app1-ijms-22-12636"><title>Supplementary Materials</title><p>The following are available online at <uri xlink:href="https://www.mdpi.com/article/10.3390/ijms222312636/s1">https://www.mdpi.com/article/10.3390/ijms222312636/s1</uri>.</p><supplementary-material id="ijms-22-12636-s001" position="float" content-type="local-data"><media xlink:href="ijms-22-12636-s001.zip"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, W.-Q.H. and J.-Q.K.; methodology, R.L.; L.-L.H.; Z.-K.J., and K.-M.L.; J.-Q.K.; writing&#x02014;original draft preparation, J.-Q.K.; writing&#x02014;review and editing, R.L; W.-Q.H.; J.-Q.K.; funding acquisition, W.-Q.H. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This work was funded by the National Key Research and Development Program of China (2018YFA0901800), the financial support from National Natural Science Foundation of China (81773617, 82073900).</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The datasets analyzed during the current study are available from the corresponding authors on reasonable request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-ijms-22-12636"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arenz</surname><given-names>S.</given-names></name>
<name><surname>Ramu</surname><given-names>H.</given-names></name>
<name><surname>Gupta</surname><given-names>P.</given-names></name>
<name><surname>Berninghausen</surname><given-names>O.</given-names></name>
<name><surname>Beckmann</surname><given-names>R.</given-names></name>
<name><surname>Vazquez-Laslop</surname><given-names>N.</given-names></name>
<name><surname>Mankin</surname><given-names>A.S.</given-names></name>
<name><surname>Wilson</surname><given-names>D.N.</given-names></name>
</person-group><article-title>Molecular basis for erythromycin-dependent ribosome stalling during translation of the ErmBL leader peptide</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>3501</fpage><pub-id pub-id-type="doi">10.1038/ncomms4501</pub-id><pub-id pub-id-type="pmid">24662426</pub-id></element-citation></ref><ref id="B2-ijms-22-12636"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chaudhary</surname><given-names>A.K.</given-names></name>
<name><surname>Hwang</surname><given-names>I.Y.</given-names></name>
<name><surname>Jo</surname><given-names>Y.J.</given-names></name>
<name><surname>Choi</surname><given-names>S.H.</given-names></name>
<name><surname>Lee</surname><given-names>E.Y.</given-names></name>
</person-group><article-title>Enzymatic synthesis of amentoflavone glycoside using recombinant oleandomycin glycosyltransferase</article-title><source>J. Ind. Eng. Chem.</source><year>2015</year><volume>25</volume><fpage>304</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1016/j.jiec.2014.11.008</pub-id></element-citation></ref><ref id="B3-ijms-22-12636"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Choi</surname><given-names>S.H.</given-names></name>
<name><surname>Ryu</surname><given-names>M.</given-names></name>
<name><surname>Yoon</surname><given-names>Y.J.</given-names></name>
<name><surname>Kim</surname><given-names>D.M.</given-names></name>
<name><surname>Lee</surname><given-names>E.Y.</given-names></name>
</person-group><article-title>Glycosylation of various flavonoids by recombinant oleandomycin glycosyltransferase from <italic toggle="yes">Streptomyces antibioticus</italic> in batch and repeated batch modes</article-title><source>Biotechnol. Lett.</source><year>2012</year><volume>34</volume><fpage>499</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1007/s10529-011-0789-z</pub-id><pub-id pub-id-type="pmid">22116386</pub-id></element-citation></ref><ref id="B4-ijms-22-12636"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>G.</given-names></name>
<name><surname>Zhu</surname><given-names>B.</given-names></name>
<name><surname>Ren</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
</person-group><article-title>Universal response method for the quantitative analysis of multi-components in josamycin and midecamycin using liquid chromatography coupled with charged aerosol detector</article-title><source>J. Pharm. Biomed. Anal.</source><year>2021</year><volume>192</volume><fpage>113679</fpage><pub-id pub-id-type="doi">10.1016/j.jpba.2020.113679</pub-id><pub-id pub-id-type="pmid">33120309</pub-id></element-citation></ref><ref id="B5-ijms-22-12636"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>Z.</given-names></name>
<name><surname>Jin</surname><given-names>L.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Zhu</surname><given-names>D.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>C.</given-names></name>
<name><surname>Lei</surname><given-names>P.</given-names></name>
</person-group><article-title>Synthesis and antibacterial activity of a series of novel 9-<italic toggle="yes">O</italic>-acetyl-4&#x02032;-substituted 16-membered macrolides derived from josamycin</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2014</year><volume>24</volume><fpage>480</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2013.12.029</pub-id><pub-id pub-id-type="pmid">24374276</pub-id></element-citation></ref><ref id="B6-ijms-22-12636"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>N.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
</person-group><article-title>In vitro activities of acetylmidecamycin and other antimicrobials against human macrolide-resistant <italic toggle="yes">Mycoplasma pneumoniae</italic> isolates</article-title><source>J. Antimicrob. Chemother.</source><year>2020</year><volume>75</volume><fpage>1513</fpage><lpage>1517</lpage><pub-id pub-id-type="doi">10.1093/jac/dkaa027</pub-id><?supplied-pmid 32073604?><pub-id pub-id-type="pmid">32073604</pub-id></element-citation></ref><ref id="B7-ijms-22-12636"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dai</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>He</surname><given-names>W.</given-names></name>
</person-group><article-title>The regulatory genes involved in spiramycin and bitespiramycin biosynthesis</article-title><source>Microbiol. Res.</source><year>2020</year><volume>240</volume><fpage>126532</fpage><pub-id pub-id-type="doi">10.1016/j.micres.2020.126532</pub-id><pub-id pub-id-type="pmid">32622100</pub-id></element-citation></ref><ref id="B8-ijms-22-12636"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Dai</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>He</surname><given-names>W.</given-names></name>
</person-group><article-title>Engineering of leucine-responsive regulatory protein improves spiramycin and bitespiramycin biosynthesis</article-title><source>Microb. Cell Fact.</source><year>2019</year><volume>18</volume><fpage>38</fpage><pub-id pub-id-type="doi">10.1186/s12934-019-1086-0</pub-id><?supplied-pmid 30782164?><pub-id pub-id-type="pmid">30782164</pub-id></element-citation></ref><ref id="B9-ijms-22-12636"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Dong</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>W.C.</given-names></name>
<name><surname>Tang</surname><given-names>B.X.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Zang</surname><given-names>Y.</given-names></name>
</person-group><article-title>Roxithromycin attenuates bleomycin-induced pulmonary fibrosis by targeting senescent cells</article-title><source>Acta Pharmacol. Sin.</source><year>2021</year><pub-id pub-id-type="doi">10.1038/s41401-021-00618-3</pub-id><?supplied-pmid 33654217?><pub-id pub-id-type="pmid">33654217</pub-id></element-citation></ref><ref id="B10-ijms-22-12636"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rossi</surname><given-names>M.</given-names></name>
<name><surname>Capecchi</surname><given-names>M.</given-names></name>
<name><surname>Lazzerini</surname><given-names>P.E.</given-names></name>
</person-group><article-title>Roxithromycin-associated acute thrombocytopenia</article-title><source>Am. J. Case Rep.</source><year>2021</year><volume>22</volume><fpage>e932039</fpage><pub-id pub-id-type="doi">10.12659/AJCR.932039</pub-id><pub-id pub-id-type="pmid">34188012</pub-id></element-citation></ref><ref id="B11-ijms-22-12636"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sidhu</surname><given-names>H.</given-names></name>
<name><surname>Bae</surname><given-names>H.S.</given-names></name>
<name><surname>Ogram</surname><given-names>A.</given-names></name>
<name><surname>O&#x02019;Connor</surname><given-names>G.</given-names></name>
<name><surname>Yu</surname><given-names>F.</given-names></name>
</person-group><article-title>Azithromycin and ciprofloxacin can promote antibiotic resistance in biosolids and biosolids-amended soils</article-title><source>Appl. Environ. Microbiol.</source><year>2021</year><volume>87</volume><fpage>e0037321</fpage><pub-id pub-id-type="doi">10.1128/AEM.00373-21</pub-id><pub-id pub-id-type="pmid">34085858</pub-id></element-citation></ref><ref id="B12-ijms-22-12636"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miao</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>R.</given-names></name>
<name><surname>Yu</surname><given-names>P.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Pan</surname><given-names>Q.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
</person-group><article-title>The macrolide antibiotic azithromycin potently inhibits hepatitis E virus in cell culture models</article-title><source>Int. J. Antimicrob. Agents</source><year>2021</year><volume>58</volume><fpage>106383</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2021.106383</pub-id><?supplied-pmid 34157403?><pub-id pub-id-type="pmid">34157403</pub-id></element-citation></ref><ref id="B13-ijms-22-12636"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>B.</given-names></name>
<name><surname>Nam</surname><given-names>S.</given-names></name>
<name><surname>Kim</surname><given-names>E.</given-names></name>
<name><surname>Jeon</surname><given-names>H.</given-names></name>
<name><surname>Lee</surname><given-names>K.</given-names></name>
<name><surname>Xie</surname><given-names>K.</given-names></name>
</person-group><article-title>Identification of erythromycin and clarithromycin metabolites formed in chicken liver microsomes using liquid chromatography-high-resolution mass spectrometry</article-title><source>Foods</source><year>2021</year><volume>10</volume><elocation-id>1504</elocation-id><pub-id pub-id-type="doi">10.3390/foods10071504</pub-id><?supplied-pmid 34209740?><pub-id pub-id-type="pmid">34209740</pub-id></element-citation></ref><ref id="B14-ijms-22-12636"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saruuljavkhlan</surname><given-names>B.</given-names></name>
<name><surname>Yamaoka</surname><given-names>Y.</given-names></name>
</person-group><article-title>Benefits of a molecular-based method for the detection of clarithromycin-resistant Helicobacter pylori</article-title><source>Gut Liver</source><year>2021</year><volume>15</volume><fpage>487</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.5009/gnl210278</pub-id><?supplied-pmid 34261816?><pub-id pub-id-type="pmid">34261816</pub-id></element-citation></ref><ref id="B15-ijms-22-12636"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Breiner-Goldstein</surname><given-names>E.</given-names></name>
<name><surname>Eyal</surname><given-names>Z.</given-names></name>
<name><surname>Matzov</surname><given-names>D.</given-names></name>
<name><surname>Halfon</surname><given-names>Y.</given-names></name>
<name><surname>Cimicata</surname><given-names>G.</given-names></name>
<name><surname>Baum</surname><given-names>M.</given-names></name>
<name><surname>Rokney</surname><given-names>A.</given-names></name>
<name><surname>Ezernitchi</surname><given-names>A.V.</given-names></name>
<name><surname>Lowell</surname><given-names>A.N.</given-names></name>
<name><surname>Schmidt</surname><given-names>J.J.</given-names></name>
<etal/>
</person-group><article-title>Ribosome-binding and anti-microbial studies of the mycinamicins, 16-membered macrolide antibiotics from <italic toggle="yes">Micromonospora griseorubida</italic></article-title><source>Nucleic Acids Res.</source><year>2021</year><volume>49</volume><fpage>9560</fpage><lpage>9573</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab684</pub-id><?supplied-pmid 34417608?><pub-id pub-id-type="pmid">34417608</pub-id></element-citation></ref><ref id="B16-ijms-22-12636"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>V&#x000e1;zquez-Laslop</surname><given-names>N.</given-names></name>
<name><surname>Mankin</surname><given-names>A.S.</given-names></name>
</person-group><article-title>How macrolide antibiotics work</article-title><source>Trends Biochem. Sci.</source><year>2018</year><volume>43</volume><fpage>668</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2018.06.011</pub-id><pub-id pub-id-type="pmid">30054232</pub-id></element-citation></ref><ref id="B17-ijms-22-12636"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wilson</surname><given-names>D.N.</given-names></name>
</person-group><article-title>Ribosome-targeting antibiotics and mechanisms of bacterial resistance</article-title><source>Nat. Rev. Microbiol.</source><year>2014</year><volume>12</volume><fpage>35</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3155</pub-id><pub-id pub-id-type="pmid">24336183</pub-id></element-citation></ref><ref id="B18-ijms-22-12636"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Golkar</surname><given-names>T.</given-names></name>
<name><surname>Zieli&#x00144;ski</surname><given-names>M.</given-names></name>
<name><surname>Berghuis</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Look and outlook on enzyme-mediated macrolide resistance</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><fpage>1942</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.01942</pub-id><pub-id pub-id-type="pmid">30177927</pub-id></element-citation></ref><ref id="B19-ijms-22-12636"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matsuoka</surname><given-names>M.</given-names></name>
<name><surname>Sasaki</surname><given-names>T.</given-names></name>
</person-group><article-title>Inactivation of macrolides by producers and pathogens</article-title><source>Curr. Drug Targets Infect. Disord.</source><year>2004</year><volume>4</volume><fpage>217</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.2174/1568005043340696</pub-id><pub-id pub-id-type="pmid">15379733</pub-id></element-citation></ref><ref id="B20-ijms-22-12636"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wright</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Bacterial resistance to antibiotics: Enzymatic degradation and modification</article-title><source>Adv. Drug Deliv. Rev.</source><year>2005</year><volume>57</volume><fpage>1451</fpage><lpage>1470</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2005.04.002</pub-id><pub-id pub-id-type="pmid">15950313</pub-id></element-citation></ref><ref id="B21-ijms-22-12636"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peterson</surname><given-names>E.</given-names></name>
<name><surname>Kaur</surname><given-names>P.</given-names></name>
</person-group><article-title>Antibiotic resistance mechanisms in bacteria: Relationships between resistance determinants of antibiotic producers, environmental bacteria, and clinical pathogens</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><fpage>2928</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.02928</pub-id><pub-id pub-id-type="pmid">30555448</pub-id></element-citation></ref><ref id="B22-ijms-22-12636"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Egorov</surname><given-names>A.M.</given-names></name>
<name><surname>Ulyashova</surname><given-names>M.M.</given-names></name>
<name><surname>Rubtsova</surname><given-names>M.Y.</given-names></name>
</person-group><article-title>Bacterial enzymes and antibiotic resistance</article-title><source>Acta Nat.</source><year>2018</year><volume>10</volume><fpage>33</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.32607/20758251-2018-10-4-33-48</pub-id></element-citation></ref><ref id="B23-ijms-22-12636"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hopwood</surname><given-names>D.A.</given-names></name>
</person-group><article-title>How do antibiotic-producing bacteria ensure their self-resistance before antibiotic biosynthesis incapacitates them?</article-title><source>Mol. Microbiol.</source><year>2007</year><volume>63</volume><fpage>937</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2006.05584.x</pub-id><pub-id pub-id-type="pmid">17238916</pub-id></element-citation></ref><ref id="B24-ijms-22-12636"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuo</surname><given-names>M.-S.</given-names></name>
<name><surname>Chirby</surname><given-names>D.</given-names></name>
<name><surname>Argoudelis</surname><given-names>A.</given-names></name>
<name><surname>Cialdella</surname><given-names>J.</given-names></name>
<name><surname>Coats</surname><given-names>J.</given-names></name>
<name><surname>Marshall</surname><given-names>V.</given-names></name>
</person-group><article-title>Microbial glycosylation of erythromycin A</article-title><source>Antimicrob. Agents Chemother.</source><year>1989</year><volume>33</volume><fpage>2089</fpage><lpage>2091</lpage><pub-id pub-id-type="doi">10.1128/AAC.33.12.2089</pub-id><pub-id pub-id-type="pmid">2619274</pub-id></element-citation></ref><ref id="B25-ijms-22-12636"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jenkins</surname><given-names>G.</given-names></name>
<name><surname>Cundliffe</surname><given-names>E.</given-names></name>
</person-group><article-title>Cloning and characterization of two genes from <italic toggle="yes">Streptomyces lividans</italic> that confer inducible resistance to lincomycin and macrolide antibiotics</article-title><source>Gene</source><year>1991</year><volume>108</volume><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/0378-1119(91)90487-V</pub-id><pub-id pub-id-type="pmid">1761231</pub-id></element-citation></ref><ref id="B26-ijms-22-12636"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cundliffe</surname><given-names>E.</given-names></name>
</person-group><article-title>Resistance to macrolides and lincosamides in <italic toggle="yes">Streptomyces lividans</italic> and to aminoglycosides in <italic toggle="yes">Micromonospora purpurea</italic></article-title><source>Gene</source><year>1992</year><volume>115</volume><fpage>75</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/0378-1119(92)90543-X</pub-id><pub-id pub-id-type="pmid">1612452</pub-id></element-citation></ref><ref id="B27-ijms-22-12636"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cundliffe</surname><given-names>E.</given-names></name>
</person-group><article-title>Glycosylation of macrolide antibiotics in extracts of <italic toggle="yes">Streptomyces lividans</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>1992</year><volume>36</volume><fpage>348</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1128/AAC.36.2.348</pub-id><?supplied-pmid 1605601?><pub-id pub-id-type="pmid">1605601</pub-id></element-citation></ref><ref id="B28-ijms-22-12636"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vilches</surname><given-names>C.</given-names></name>
<name><surname>Hernandez</surname><given-names>C.</given-names></name>
<name><surname>Mendez</surname><given-names>C.</given-names></name>
<name><surname>Salas</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Role of glycosylation and deglycosylation in biosynthesis of and resistance to oleandomycin in the producer organism, <italic toggle="yes">Streptomyces antibioticus</italic></article-title><source>J. Bacteriol.</source><year>1992</year><volume>174</volume><fpage>161</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1128/jb.174.1.161-165.1992</pub-id><?supplied-pmid 1530845?><pub-id pub-id-type="pmid">1530845</pub-id></element-citation></ref><ref id="B29-ijms-22-12636"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hern&#x000e1;ndez</surname><given-names>C.</given-names></name>
<name><surname>Olano</surname><given-names>C.</given-names></name>
<name><surname>M&#x000e9;ndez</surname><given-names>C.</given-names></name>
<name><surname>Salas</surname><given-names>J.</given-names></name>
</person-group><article-title>Characterization of a <italic toggle="yes">Streptomyces antibioticus</italic> gene cluster encoding a glycosyltransferase involved in oleandomycin inactivation</article-title><source>Gene</source><year>1993</year><volume>134</volume><fpage>139</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/0378-1119(93)90189-A</pub-id><pub-id pub-id-type="pmid">8244027</pub-id></element-citation></ref><ref id="B30-ijms-22-12636"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quir&#x000f3;s</surname><given-names>L.M.</given-names></name>
<name><surname>Salas</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Biosynthesis of the macrolide oleandomycin by <italic toggle="yes">Streptomyces antibioticus</italic>: Purification and kinetic characterization of an oleandomycin glucosyltransferase</article-title><source>J. Biol. Chem.</source><year>1995</year><volume>270</volume><fpage>18234</fpage><lpage>18239</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.31.18234</pub-id><pub-id pub-id-type="pmid">7629141</pub-id></element-citation></ref><ref id="B31-ijms-22-12636"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quir&#x000f3;s</surname><given-names>L.M.</given-names></name>
<name><surname>Aguirrezabalaga</surname><given-names>I.</given-names></name>
<name><surname>Olano</surname><given-names>C.</given-names></name>
<name><surname>M&#x000e9;ndez</surname><given-names>C.</given-names></name>
<name><surname>Salas</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Two glycosyltransferases and a glycosidase are involved in oleandomycin modification during its biosynthesis by <italic toggle="yes">Streptomyces antibioticus</italic></article-title><source>Mol. Microbiol.</source><year>1998</year><volume>28</volume><fpage>1177</fpage><lpage>1185</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.1998.00880.x</pub-id><?supplied-pmid 9680207?><pub-id pub-id-type="pmid">9680207</pub-id></element-citation></ref><ref id="B32-ijms-22-12636"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quir&#x000f3;s</surname><given-names>L.M.</given-names></name>
<name><surname>Carbajo</surname><given-names>R.J.</given-names></name>
<name><surname>Salas</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Inversion of the anomeric configuration of the transferred sugar during inactivation of the macrolide antibiotic oleandomycin catalyzed by a macrolide glycosyltransferase</article-title><source>FEBS Lett.</source><year>2000</year><volume>476</volume><fpage>186</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(00)01721-X</pub-id><pub-id pub-id-type="pmid">10913610</pub-id></element-citation></ref><ref id="B33-ijms-22-12636"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schulman</surname><given-names>M.</given-names></name>
<name><surname>Doherty</surname><given-names>P.</given-names></name>
<name><surname>Arison</surname><given-names>B.</given-names></name>
</person-group><article-title>Microbial conversion of avermectins by <italic toggle="yes">Saccharopolyspora erythraea: Glycosylation</italic> at C-4&#x02032; and C-4&#x02033;</article-title><source>Antimicrob. Agents Chemother.</source><year>1993</year><volume>37</volume><fpage>1737</fpage><lpage>1741</lpage><pub-id pub-id-type="doi">10.1128/AAC.37.9.1737</pub-id><pub-id pub-id-type="pmid">8239577</pub-id></element-citation></ref><ref id="B34-ijms-22-12636"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yazawa</surname><given-names>K.</given-names></name>
<name><surname>Mikami</surname><given-names>Y.</given-names></name>
<name><surname>Sakamoto</surname><given-names>T.</given-names></name>
<name><surname>Ueno</surname><given-names>Y.</given-names></name>
<name><surname>Morisaki</surname><given-names>N.</given-names></name>
<name><surname>Iwasaki</surname><given-names>S.</given-names></name>
<name><surname>Furihata</surname><given-names>K.</given-names></name>
</person-group><article-title>Inactivation of the macrolide antibiotics erythromycin, midecamycin, and rokitamycin by pathogenic Nocardia species</article-title><source>Antimicrob. Agents Chemother.</source><year>1994</year><volume>38</volume><fpage>2197</fpage><lpage>2199</lpage><pub-id pub-id-type="doi">10.1128/AAC.38.9.2197</pub-id><pub-id pub-id-type="pmid">7811046</pub-id></element-citation></ref><ref id="B35-ijms-22-12636"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morisaki</surname><given-names>N.</given-names></name>
<name><surname>Hashimoto</surname><given-names>Y.</given-names></name>
<name><surname>Furihata</surname><given-names>K.</given-names></name>
<name><surname>Yazawa</surname><given-names>K.</given-names></name>
<name><surname>Tamura</surname><given-names>M.</given-names></name>
<name><surname>Mikami</surname><given-names>Y.</given-names></name>
</person-group><article-title>Glycosylative inactivation of chalcomycin and tylosin by a clinically isolated <italic toggle="yes">Nocardia asteroides</italic> strain</article-title><source>J. Antibiot.</source><year>2001</year><volume>54</volume><fpage>157</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.54.157</pub-id><?supplied-pmid 11302489?><pub-id pub-id-type="pmid">11302489</pub-id></element-citation></ref><ref id="B36-ijms-22-12636"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sasaki</surname><given-names>J.</given-names></name>
<name><surname>Mizoue</surname><given-names>K.</given-names></name>
<name><surname>Morimoto</surname><given-names>S.</given-names></name>
<name><surname>Omura</surname><given-names>S.</given-names></name>
</person-group><article-title>Microbial glycosylation of macrolide antibiotics by <italic toggle="yes">Streptomyces hygroscopicus</italic> ATCC 31080 and distribution of a macrolide glycosyl transferase in several <italic toggle="yes">Streptomyces</italic> strains</article-title><source>J. Antibiot.</source><year>1996</year><volume>49</volume><fpage>1110</fpage><lpage>1118</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.49.1110</pub-id></element-citation></ref><ref id="B37-ijms-22-12636"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gourmelen</surname><given-names>A.</given-names></name>
<name><surname>Blondelet-Rouault</surname><given-names>M.H.</given-names></name>
<name><surname>Pernodet</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Characterization of a glycosyl transferase inactivating macrolides, encoded by gimA from <italic toggle="yes">Streptomyces ambofaciens</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>1998</year><volume>42</volume><fpage>2612</fpage><lpage>2619</lpage><pub-id pub-id-type="doi">10.1128/AAC.42.10.2612</pub-id><pub-id pub-id-type="pmid">9756764</pub-id></element-citation></ref><ref id="B38-ijms-22-12636"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>P.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Yue</surname><given-names>X.-J.</given-names></name>
<name><surname>Tang</surname><given-names>Y.-J.</given-names></name>
<name><surname>Wu</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>Y.-Z.</given-names></name>
</person-group><article-title>Effects of glycosylation on the bioactivity of rapamycin</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2020</year><volume>104</volume><fpage>9125</fpage><lpage>9134</lpage><pub-id pub-id-type="doi">10.1007/s00253-020-10895-3</pub-id><pub-id pub-id-type="pmid">32940736</pub-id></element-citation></ref><ref id="B39-ijms-22-12636"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>P.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>Z.-F.</given-names></name>
<name><surname>Chen</surname><given-names>Q.</given-names></name>
<name><surname>Li</surname><given-names>Y.-Y.</given-names></name>
<name><surname>Gong</surname><given-names>Y.</given-names></name>
<name><surname>Yue</surname><given-names>X.-J.</given-names></name>
<name><surname>Sheng</surname><given-names>D.-H.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.-M.</given-names></name>
<name><surname>Wu</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Phylogeny-guided characterization of glycosyltransferases for epothilone glycosylation</article-title><source>Microb. Biotechnol.</source><year>2019</year><volume>12</volume><fpage>763</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1111/1751-7915.13421</pub-id><pub-id pub-id-type="pmid">31069998</pub-id></element-citation></ref><ref id="B40-ijms-22-12636"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>M.</given-names></name>
<name><surname>Proctor</surname><given-names>M.R.</given-names></name>
<name><surname>Bolam</surname><given-names>D.N.</given-names></name>
<name><surname>Errey</surname><given-names>J.C.</given-names></name>
<name><surname>Field</surname><given-names>R.A.</given-names></name>
<name><surname>Gilbert</surname><given-names>H.J.</given-names></name>
<name><surname>Davis</surname><given-names>B.G.</given-names></name>
</person-group><article-title>Probing the breadth of macrolide glycosyltransferases:&#x02009; in vitro remodeling of a polyketide antibiotic creates active bacterial uptake and enhances potency</article-title><source>J. Am. Chem. Soc.</source><year>2005</year><volume>127</volume><fpage>9336</fpage><lpage>9337</lpage><pub-id pub-id-type="doi">10.1021/ja051482n</pub-id><?supplied-pmid 15984838?><pub-id pub-id-type="pmid">15984838</pub-id></element-citation></ref><ref id="B41-ijms-22-12636"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bolam</surname><given-names>D.N.</given-names></name>
<name><surname>Roberts</surname><given-names>S.</given-names></name>
<name><surname>Proctor</surname><given-names>M.R.</given-names></name>
<name><surname>Turkenburg</surname><given-names>J.P.</given-names></name>
<name><surname>Dodson</surname><given-names>E.J.</given-names></name>
<name><surname>Martinez-Fleites</surname><given-names>C.</given-names></name>
<name><surname>Yang</surname><given-names>M.</given-names></name>
<name><surname>Davis</surname><given-names>B.G.</given-names></name>
<name><surname>Davies</surname><given-names>G.J.</given-names></name>
<name><surname>Gilbert</surname><given-names>H.J.</given-names></name>
</person-group><article-title>The crystal structure of two macrolide glycosyltransferases provides a blueprint for host cell antibiotic immunity</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2007</year><volume>104</volume><fpage>5336</fpage><lpage>5341</lpage><pub-id pub-id-type="doi">10.1073/pnas.0607897104</pub-id><?supplied-pmid 17376874?><pub-id pub-id-type="pmid">17376874</pub-id></element-citation></ref><ref id="B42-ijms-22-12636"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quiros</surname><given-names>L.M.</given-names></name>
<name><surname>Carbajo</surname><given-names>R.J.</given-names></name>
<name><surname>Brana</surname><given-names>A.F.</given-names></name>
<name><surname>Salas</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Glycosylation of macrolide antibiotics. Purification and kinetic studies of a macrolide glycosyltransferase from <italic toggle="yes">Streptomyces antibioticus</italic></article-title><source>J. Biol. Chem.</source><year>2000</year><volume>275</volume><fpage>11713</fpage><lpage>11720</lpage><?supplied-pmid 10766792?><pub-id pub-id-type="pmid">10766792</pub-id></element-citation></ref><ref id="B43-ijms-22-12636"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quiros</surname><given-names>L.M.</given-names></name>
<name><surname>Hernandez</surname><given-names>C.</given-names></name>
<name><surname>Salas</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Purification and characterization of an extracellular enzyme from <italic toggle="yes">Streptomyces antibioticus</italic> that converts inactive glycosylated oleandomycin into the active antibiotic</article-title><source>Eur. J. Biochem.</source><year>1994</year><volume>222</volume><fpage>129</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.1994.tb18850.x</pub-id><pub-id pub-id-type="pmid">8200337</pub-id></element-citation></ref><ref id="B44-ijms-22-12636"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arsic</surname><given-names>B.</given-names></name>
<name><surname>Barber</surname><given-names>J.</given-names></name>
<name><surname>&#x0010c;iko&#x00161;</surname><given-names>A.</given-names></name>
<name><surname>Mladenovic</surname><given-names>M.</given-names></name>
<name><surname>Stankovic</surname><given-names>N.</given-names></name>
<name><surname>Novak</surname><given-names>P.</given-names></name>
</person-group><article-title>16-membered macrolide antibiotics: A review</article-title><source>Int. J. Antimicrob. Agents</source><year>2018</year><volume>51</volume><fpage>283</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2017.05.020</pub-id><pub-id pub-id-type="pmid">28668674</pub-id></element-citation></ref><ref id="B45-ijms-22-12636"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cong</surname><given-names>L.</given-names></name>
<name><surname>Piepersberg</surname><given-names>W.</given-names></name>
</person-group><article-title>Cloning and characterization of genes encoded in dTDP-D-mycaminose biosynthetic pathway from a midecamycin-producing strain, <italic toggle="yes">Streptomyces mycarofaciens</italic></article-title><source>Acta Biochim. Biophys. Sin.</source><year>2007</year><volume>39</volume><fpage>187</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1111/j.1745-7270.2007.00265.x</pub-id><pub-id pub-id-type="pmid">17342257</pub-id></element-citation></ref><ref id="B46-ijms-22-12636"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cui</surname><given-names>W.</given-names></name>
<name><surname>Ma</surname><given-names>S.</given-names></name>
</person-group><article-title>Recent advances in the field of 16-membered macrolide antibiotics</article-title><source>Mini-Rev. Med. Chem.</source><year>2011</year><volume>11</volume><fpage>1009</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.2174/138955711797247734</pub-id><pub-id pub-id-type="pmid">21861810</pub-id></element-citation></ref><ref id="B47-ijms-22-12636"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schlegel</surname><given-names>L.</given-names></name>
<name><surname>Merad</surname><given-names>B.</given-names></name>
<name><surname>Rostane</surname><given-names>H.</given-names></name>
<name><surname>Broc</surname><given-names>V.</given-names></name>
<name><surname>Bouvet</surname><given-names>A.</given-names></name>
</person-group><article-title>In vitro activity of midecamycin diacetate, a 16-membered macrolide, against <italic toggle="yes">Streptococcus pyogenes</italic> isolated in France, 1995-1999</article-title><source>Clin. Microbiol. Infect.</source><year>2001</year><volume>7</volume><fpage>362</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1046/j.1198-743x.2001.00280.x</pub-id><pub-id pub-id-type="pmid">11531981</pub-id></element-citation></ref><ref id="B48-ijms-22-12636"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>X.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Duan</surname><given-names>X.</given-names></name>
<name><surname>Lu</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>K.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Dong</surname><given-names>L.</given-names></name>
<name><surname>Sun</surname><given-names>H.</given-names></name>
</person-group><article-title>Facile fabrication of three-dimensional graphene microspheres using &#x003b2;-cyclodextrin aggregates as substrates and their application for midecamycin sensing</article-title><source>RSC Adv.</source><year>2015</year><volume>5</volume><fpage>77469</fpage><lpage>77477</lpage><pub-id pub-id-type="doi">10.1039/C5RA11819K</pub-id></element-citation></ref><ref id="B49-ijms-22-12636"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Song</surname><given-names>X.</given-names></name>
<name><surname>Zhou</surname><given-names>T.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Xie</surname><given-names>J.</given-names></name>
<name><surname>He</surname><given-names>L.</given-names></name>
</person-group><article-title>Determination of ten macrolide drugs in environmental water using molecularly imprinted solid-phase extraction coupled with liquid chromatography-tandem mass spectrometry</article-title><source>Molecules.</source><year>2018</year><volume>23</volume><elocation-id>1172</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23051172</pub-id></element-citation></ref><ref id="B50-ijms-22-12636"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Song</surname><given-names>X.</given-names></name>
<name><surname>Zhou</surname><given-names>T.</given-names></name>
<name><surname>Bian</surname><given-names>K.</given-names></name>
<name><surname>Zhang</surname><given-names>F.</given-names></name>
<name><surname>He</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>Q.</given-names></name>
</person-group><article-title>Simultaneous determination of ten macrolides drugs in feeds by high performance liquid chromatography with evaporation light scattering detection</article-title><source>RSC Adv.</source><year>2015</year><volume>5</volume><fpage>1491</fpage><lpage>1499</lpage><pub-id pub-id-type="doi">10.1039/C4RA12623H</pub-id></element-citation></ref><ref id="B51-ijms-22-12636"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>L.</given-names></name>
<name><surname>McDaniel</surname><given-names>R.</given-names></name>
</person-group><article-title>Construction of desosamine containing polyketide libraries using a glycosyltransferase with broad substrate specificity</article-title><source>Chem. Biol.</source><year>2001</year><volume>8</volume><fpage>547</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/S1074-5521(01)00032-1</pub-id><pub-id pub-id-type="pmid">11410374</pub-id></element-citation></ref><ref id="B52-ijms-22-12636"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Isiorho</surname><given-names>E.A.</given-names></name>
<name><surname>Jeon</surname><given-names>B.-S.</given-names></name>
<name><surname>Kim</surname><given-names>N.H.</given-names></name>
<name><surname>Liu</surname><given-names>H.-W.</given-names></name>
<name><surname>Keatinge-Clay</surname><given-names>A.T.</given-names></name>
</person-group><article-title>Structural studies of the spinosyn forosaminyltransferase, SpnP</article-title><source>Biochemistry</source><year>2014</year><volume>53</volume><fpage>4292</fpage><lpage>4301</lpage><pub-id pub-id-type="doi">10.1021/bi5003629</pub-id><pub-id pub-id-type="pmid">24945604</pub-id></element-citation></ref><ref id="B53-ijms-22-12636"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gaisser</surname><given-names>S.</given-names></name>
<name><surname>Carletti</surname><given-names>I.</given-names></name>
<name><surname>Schell</surname><given-names>U.</given-names></name>
<name><surname>Graupner</surname><given-names>P.R.</given-names></name>
<name><surname>Sparks</surname><given-names>T.C.</given-names></name>
<name><surname>Martin</surname><given-names>C.J.</given-names></name>
<name><surname>Wilkinson</surname><given-names>B.</given-names></name>
</person-group><article-title>Glycosylation engineering of spinosyn analogues containing an L-olivose moiety</article-title><source>Org. Biomol. Chem.</source><year>2009</year><volume>7</volume><fpage>1705</fpage><lpage>1708</lpage><pub-id pub-id-type="doi">10.1039/b900233b</pub-id><pub-id pub-id-type="pmid">19343260</pub-id></element-citation></ref><ref id="B54-ijms-22-12636"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>H.C.</given-names></name>
<name><surname>Karray</surname><given-names>F.</given-names></name>
<name><surname>Lautru</surname><given-names>S.</given-names></name>
<name><surname>Gagnat</surname><given-names>J.</given-names></name>
<name><surname>Lebrihi</surname><given-names>A.</given-names></name>
<name><surname>Huynh</surname><given-names>T.D.</given-names></name>
<name><surname>Pernodet</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Glycosylation steps during spiramycin biosynthesis in <italic toggle="yes">Streptomyces ambofaciens</italic>: Involvement of three glycosyltransferases and their interplay with two auxiliary proteins</article-title><source>Antimicrob. Agents Chemother.</source><year>2010</year><volume>54</volume><fpage>2830</fpage><lpage>2839</lpage><pub-id pub-id-type="doi">10.1128/AAC.01602-09</pub-id><pub-id pub-id-type="pmid">20439613</pub-id></element-citation></ref><ref id="B55-ijms-22-12636"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Skinner</surname><given-names>M.</given-names></name>
<name><surname>Taylor</surname><given-names>R.B.</given-names></name>
<name><surname>Kanfer</surname><given-names>I.</given-names></name>
</person-group><article-title>The pH-stability and acid degradation of the macrolide antibiotic, josamycin</article-title><source>Eur. J. Pharm. Sci.</source><year>1993</year><volume>1</volume><fpage>61</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/0928-0987(93)90019-7</pub-id></element-citation></ref><ref id="B56-ijms-22-12636"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Omoto</surname><given-names>S.</given-names></name>
<name><surname>Ogino</surname><given-names>H.</given-names></name>
<name><surname>Iwamatsu</surname><given-names>K.</given-names></name>
<name><surname>Inouye</surname><given-names>S.</given-names></name>
</person-group><article-title>Modification of the macrolide antibiotic midecamycin. III. Formation of neoisomidecamycin</article-title><source>J. Antibiot.</source><year>1982</year><volume>35</volume><fpage>1521</fpage><lpage>1526</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.35.1521</pub-id></element-citation></ref><ref id="B57-ijms-22-12636"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gantt</surname><given-names>R.W.</given-names></name>
<name><surname>Peltier-Pain</surname><given-names>P.</given-names></name>
<name><surname>Singh</surname><given-names>S.</given-names></name>
<name><surname>Zhou</surname><given-names>M.</given-names></name>
<name><surname>Thorson</surname><given-names>J.S.</given-names></name>
</person-group><article-title>Broadening the scope of glycosyltransferase-catalyzed sugar nucleotide synthesis</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>7648</fpage><lpage>7653</lpage><pub-id pub-id-type="doi">10.1073/pnas.1220220110</pub-id><pub-id pub-id-type="pmid">23610417</pub-id></element-citation></ref><ref id="B58-ijms-22-12636"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>A.</given-names></name>
<name><surname>Singh</surname><given-names>S.</given-names></name>
<name><surname>Phillips</surname><given-names>G.N.</given-names><suffix>Jr.</suffix></name>
<name><surname>Thorson</surname><given-names>J.S.</given-names></name>
</person-group><article-title>Glycosyltransferase structural biology and its role in the design of catalysts for glycosylation</article-title><source>Curr. Opin. Biotechnol.</source><year>2011</year><volume>22</volume><fpage>800</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2011.04.013</pub-id><?supplied-pmid 21592771?><pub-id pub-id-type="pmid">21592771</pub-id></element-citation></ref><ref id="B59-ijms-22-12636"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dinos</surname><given-names>G.P.</given-names></name>
</person-group><article-title>The macrolide antibiotic renaissance</article-title><source>Brit. J. Pharmacol.</source><year>2017</year><volume>174</volume><fpage>2967</fpage><lpage>2983</lpage><pub-id pub-id-type="doi">10.1111/bph.13936</pub-id><?supplied-pmid 28664582?><pub-id pub-id-type="pmid">28664582</pub-id></element-citation></ref><ref id="B60-ijms-22-12636"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malmierca</surname><given-names>M.G.</given-names></name>
<name><surname>P&#x000e9;rez-Victoria</surname><given-names>I.</given-names></name>
<name><surname>Mart&#x000ed;n</surname><given-names>J.</given-names></name>
<name><surname>Reyes</surname><given-names>F.</given-names></name>
<name><surname>M&#x000e9;ndez</surname><given-names>C.</given-names></name>
<name><surname>Salas</surname><given-names>J.A.</given-names></name>
<name><surname>Olano</surname><given-names>C.</given-names></name>
</person-group><article-title>New sipanmycin analogues generated by combinatorial biosynthesis and mutasynthesis approaches relying on the substrate flexibility of key enzymes in the biosynthetic pathway</article-title><source>Appl. Environ. Microbiol.</source><year>2020</year><volume>86</volume><fpage>e02453-19</fpage><pub-id pub-id-type="doi">10.1128/AEM.02453-19</pub-id><?supplied-pmid 31732573?><pub-id pub-id-type="pmid">31732573</pub-id></element-citation></ref><ref id="B61-ijms-22-12636"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hara</surname><given-names>O.</given-names></name>
<name><surname>Hutchinson</surname><given-names>C.R.</given-names></name>
</person-group><article-title>A macrolide 3-<italic toggle="yes">O</italic>-acyltransferase gene from the midecamycin-producing species <italic toggle="yes">Streptomyces mycarofaciens</italic></article-title><source>J. Bacteriol.</source><year>1992</year><volume>174</volume><fpage>5141</fpage><lpage>5144</lpage><pub-id pub-id-type="doi">10.1128/jb.174.15.5141-5144.1992</pub-id><pub-id pub-id-type="pmid">1629172</pub-id></element-citation></ref><ref id="B62-ijms-22-12636"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xue</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>H.-W.</given-names></name>
<name><surname>Sherman</surname><given-names>D.H.</given-names></name>
</person-group><article-title>A gene cluster for macrolide antibiotic biosynthesis in <italic toggle="yes">Streptomyces venezuelae</italic>: Architecture of metabolic diversity</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1998</year><volume>95</volume><fpage>12111</fpage><lpage>12116</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.21.12111</pub-id><?supplied-pmid 9770448?><pub-id pub-id-type="pmid">9770448</pub-id></element-citation></ref><ref id="B63-ijms-22-12636"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Waldron</surname><given-names>C.</given-names></name>
<name><surname>Matsushima</surname><given-names>P.</given-names></name>
<name><surname>Rosteck</surname><given-names>P.R.</given-names></name>
<name><surname>Broughton</surname><given-names>M.C.</given-names></name>
<name><surname>Turner</surname><given-names>J.</given-names></name>
<name><surname>Madduri</surname><given-names>K.</given-names></name>
<name><surname>Crawford</surname><given-names>K.P.</given-names></name>
<name><surname>Merlo</surname><given-names>D.J.</given-names></name>
<name><surname>Baltz</surname><given-names>R.H.</given-names></name>
</person-group><article-title>Cloning and analysis of the spinosad biosynthetic gene cluster of <italic toggle="yes">Saccharopolyspora spinosa</italic></article-title><source>Chem. Biol.</source><year>2001</year><volume>8</volume><fpage>487</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1016/S1074-5521(01)00029-1</pub-id><pub-id pub-id-type="pmid">11358695</pub-id></element-citation></ref><ref id="B64-ijms-22-12636"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>X.-N.</given-names></name>
<name><surname>Hong</surname><given-names>L.-L.</given-names></name>
<name><surname>Kong</surname><given-names>J.-Q.</given-names></name>
</person-group><article-title>Diacerein as a promising acyl donor in biosynthetic acetyl-CoA and glycosyl esters mediated by a multifunctional maltose <italic toggle="yes">O</italic>-acetyltransferase from <italic toggle="yes">Escherichia coli</italic></article-title><source>J. Agric. Food Chem.</source><year>2021</year><volume>69</volume><fpage>6623</fpage><lpage>6635</lpage><pub-id pub-id-type="doi">10.1021/acs.jafc.1c01779</pub-id><pub-id pub-id-type="pmid">34080854</pub-id></element-citation></ref><ref id="B65-ijms-22-12636"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Veseli</surname><given-names>A.</given-names></name>
<name><surname>&#x0017d;akelj</surname><given-names>S.</given-names></name>
<name><surname>Kristl</surname><given-names>A.</given-names></name>
</person-group><article-title>A review of methods for solubility determination in biopharmaceutical drug characterization</article-title><source>Drug Dev. Ind. Pharm.</source><year>2019</year><volume>45</volume><fpage>1717</fpage><lpage>1724</lpage><pub-id pub-id-type="doi">10.1080/03639045.2019.1665062</pub-id><?supplied-pmid 31512934?><pub-id pub-id-type="pmid">31512934</pub-id></element-citation></ref><ref id="B66-ijms-22-12636"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>W.</given-names></name>
<name><surname>Yang</surname><given-names>C.</given-names></name>
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
</person-group><article-title>Antimicrobial activity of bitespiramycin, a new genetically engineered macrolide</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2017</year><volume>27</volume><fpage>4576</fpage><lpage>4577</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2017.08.046</pub-id><?supplied-pmid 28867456?><pub-id pub-id-type="pmid">28867456</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="ijms-22-12636-f001"><label>Figure 1</label><caption><p>OleD-catalyzed glycodiversification towards midecamycin.</p></caption><graphic xlink:href="ijms-22-12636-g001" position="float"/></fig><fig position="float" id="ijms-22-12636-f002"><label>Figure 2</label><caption><p>OleD-catalyzed glucosylation towards midecamycin. (<bold>A</bold>), SDS-PAGE analysis of purified OleD. M, Protein marker indicated in kDa in the left margin; 1, Induced <italic toggle="yes">E. coli</italic> harboring pET-His empty vector; 2, Soluble fraction of OleD; 3, The purified OleD. The arrows showed the expressing OleD protein. (<bold>B</bold>), Glucosylation of midecamycin catalyzed by the purified OleD(e), Srm29(d), SpnP(c), DesVII (b) or no protein (a), which were separated by HPLC. 1, 1a and 1b referred to midecamycin and its monoglucosylated products. Arrows showed the glucosylated products. (<bold>C</bold>), UV spectrum of midecamycin (1) and its glucosylated products (1a and 1b). (<bold>D</bold>), HR-MS spectrum of 1a with <italic toggle="yes">m/z</italic> value of 976.5081. (<bold>E</bold>), HR-MS spectrum of 1b with <italic toggle="yes">m/z</italic> value of 976.5082. (<bold>F</bold>), HR-MS spectrum of midecamycin with <italic toggle="yes">m/z</italic> value of 814.4577.</p></caption><graphic xlink:href="ijms-22-12636-g002" position="float"/></fig><fig position="float" id="ijms-22-12636-f003"><label>Figure 3</label><caption><p>OleD-catalyzed glycodiversification towards midecamycin. (<bold>A</bold>), OleD-catalyzed reaction of midecamycin with UDP-Glc (a), UDP-Xyl (b), UDP-Gal (c), UDP-Rha (d), UDP-GlcNAc (e), or without a donor (f); (<bold>B</bold>), The conversions of midecamycin with UDP-Glc, UDP-Xyl, UDP-Gal, UDP-Rha and UDP-GlcNAc, respectively; (<bold>C</bold>), HR-MS spectrum of 1c with <italic toggle="yes">m/z</italic> value of 946.4982; (<bold>D</bold>), HR-MS spectrum of 1d with <italic toggle="yes">m/z</italic> value of 946.4995; (<bold>E</bold>), UV spectra of 1, 1c and 1d.</p></caption><graphic xlink:href="ijms-22-12636-g003" position="float"/></fig><fig position="float" id="ijms-22-12636-f004"><label>Figure 4</label><caption><p>The conversions of OleD and its Q327 mutants towards UDP-GlcNAc. (<bold>A</bold>), SDS-PAGE analyses of the purified OleD and its Q327 variants. M, Protein marker, indicated as kDa in the left margin of the gel; 1, induced <italic toggle="yes">E. coli</italic> harboring pET-His empty vector; 2, wild type OleD, 3, Q327F; 4, Q327H; 5, Q327M; 6, Q327R; 7, Q327W; (<bold>B</bold>), The conversions of Q327 mutants towards UDP-GlcNAc.</p></caption><graphic xlink:href="ijms-22-12636-g004" position="float"/></fig><table-wrap position="float" id="ijms-22-12636-t001"><object-id pub-id-type="pii">ijms-22-12636-t001_Table 1</object-id><label>Table 1</label><caption><p>NMR data of 1a and 1c in CD<sub>3</sub>OD.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">1a</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">1c</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Position</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b4;<sub>C</sub></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b4;<sub>H</sub> (mult, <italic toggle="yes">J</italic> Hz)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b4;<sub>C</sub></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b4;<sub>H</sub> (mult, <italic toggle="yes">J</italic> Hz)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">172.3</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">172.2</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">37.9</td><td align="center" valign="middle" rowspan="1" colspan="1">2.65 (dd, 12.3, 12.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">37.9</td><td align="center" valign="middle" rowspan="1" colspan="1">2.65 (overlap)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.41 (dd, 13.2, 5.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.37 (dd, 12.3, 7.6)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">71.1</td><td align="center" valign="middle" rowspan="1" colspan="1">5.09&#x02013;5.14 (m)</td><td align="center" valign="middle" rowspan="1" colspan="1">71.1</td><td align="center" valign="middle" rowspan="1" colspan="1">5.08&#x02013;5.13 (m)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">85.7</td><td align="center" valign="middle" rowspan="1" colspan="1">3.54 (dd, 10.2, 6.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">85.9</td><td align="center" valign="middle" rowspan="1" colspan="1">3.38 (overlap)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">76.8</td><td align="center" valign="middle" rowspan="1" colspan="1">3.87 (overlap)</td><td align="center" valign="middle" rowspan="1" colspan="1">76.3</td><td align="center" valign="middle" rowspan="1" colspan="1">3.89 (overlap)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">30.2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.13&#x02013;2.21 (m)</td><td align="center" valign="middle" rowspan="1" colspan="1">30.1</td><td align="center" valign="middle" rowspan="1" colspan="1">2.14&#x02013;2.23 (m)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">31.6</td><td align="center" valign="middle" rowspan="1" colspan="1">1.48&#x02013;1.56 (m)</td><td align="center" valign="middle" rowspan="1" colspan="1">32.6</td><td align="center" valign="middle" rowspan="1" colspan="1">1.52&#x02013;1.61 (m)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1.07&#x02013;1.13 (m)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.98&#x02013;1.03 (m)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">35.2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.86&#x02013;1.95 (m)</td><td align="center" valign="middle" rowspan="1" colspan="1">35.1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.92&#x02013;2.00 (m)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">74.1</td><td align="center" valign="middle" rowspan="1" colspan="1">4.23 (dd, 9.6, 5.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">74.1</td><td align="center" valign="middle" rowspan="1" colspan="1">4.22 (dd, 9.6, 7.6)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">128.8</td><td align="center" valign="middle" rowspan="1" colspan="1">5.64 (dd, 15.6, 9.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">128.6</td><td align="center" valign="middle" rowspan="1" colspan="1">5.65 (dd, 15.3, 5.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">136.6</td><td align="center" valign="middle" rowspan="1" colspan="1">6.58 (dd, 16.0, 10.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">136.7</td><td align="center" valign="middle" rowspan="1" colspan="1">6.59 (dd, 15.2, 10.4)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">133.9</td><td align="center" valign="middle" rowspan="1" colspan="1">6.10 (dd,15.0, 10.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">133.8</td><td align="center" valign="middle" rowspan="1" colspan="1">6.11 (dd, 14.9, 10.6)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">133.2</td><td align="center" valign="middle" rowspan="1" colspan="1">5.71&#x02013;5.78 (m)</td><td align="center" valign="middle" rowspan="1" colspan="1">133.3</td><td align="center" valign="middle" rowspan="1" colspan="1">5.71&#x02013;5.79 (m)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">41.8</td><td align="center" valign="middle" rowspan="1" colspan="1">2.13&#x02013;2.21 (m)</td><td align="center" valign="middle" rowspan="1" colspan="1">42.8</td><td align="center" valign="middle" rowspan="1" colspan="1">2.47&#x02013;2.51 (m)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.45&#x02013;2.50 (m)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.16&#x02013;2.22 (m)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">70.6</td><td align="center" valign="middle" rowspan="1" colspan="1">4.94 (dd, 13.8, 6.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">70.7</td><td align="center" valign="middle" rowspan="1" colspan="1">4.93 (dd, 10.0, 6.5)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">20.6</td><td align="center" valign="middle" rowspan="1" colspan="1">1.25 (d, 6.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">20.9</td><td align="center" valign="middle" rowspan="1" colspan="1">1.27 (d, 5.6)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">43.5</td><td align="center" valign="middle" rowspan="1" colspan="1">2.82&#x02013;2.90 (m)</td><td align="center" valign="middle" rowspan="1" colspan="1">43.4</td><td align="center" valign="middle" rowspan="1" colspan="1">2.83 (dd, 18.6, 11.3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.36 (dd, 18.0, 7.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.36 (overlap)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">203.5</td><td align="center" valign="middle" rowspan="1" colspan="1">9.66 (s)</td><td align="center" valign="middle" rowspan="1" colspan="1">203.5</td><td align="center" valign="middle" rowspan="1" colspan="1">9.66 (s)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">15.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.99 (t, 5.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">15.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.99 (d, 5.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">175.8</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">175.8</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">21</td><td align="center" valign="middle" rowspan="1" colspan="1">28.5</td><td align="center" valign="middle" rowspan="1" colspan="1">2.43&#x02013;2.49 (m)</td><td align="center" valign="middle" rowspan="1" colspan="1">28.5</td><td align="center" valign="middle" rowspan="1" colspan="1">2.41&#x02013;2.49 (m)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">9.6</td><td align="center" valign="middle" rowspan="1" colspan="1">1.19 (overlap)</td><td align="center" valign="middle" rowspan="1" colspan="1">9.6</td><td align="center" valign="middle" rowspan="1" colspan="1">1.19 (overlap)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">23</td><td align="center" valign="middle" rowspan="1" colspan="1">62.9</td><td align="center" valign="middle" rowspan="1" colspan="1">3.62 (s)</td><td align="center" valign="middle" rowspan="1" colspan="1">62.5</td><td align="center" valign="middle" rowspan="1" colspan="1">3.58 (s)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1&#x02032;</td><td align="center" valign="middle" rowspan="1" colspan="1">102.7</td><td align="center" valign="middle" rowspan="1" colspan="1">4.69</td><td align="center" valign="middle" rowspan="1" colspan="1">102.1</td><td align="center" valign="middle" rowspan="1" colspan="1">4.69 (d, 7.1)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2&#x02032;</td><td align="center" valign="middle" rowspan="1" colspan="1">82.3</td><td align="center" valign="middle" rowspan="1" colspan="1">3.42 (dd, 7.8, 6.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">81.5</td><td align="center" valign="middle" rowspan="1" colspan="1">3.48 (dd, 8.9, 5.6)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3&#x02032;</td><td align="center" valign="middle" rowspan="1" colspan="1">69.7</td><td align="center" valign="middle" rowspan="1" colspan="1">2.87 (overlap)</td><td align="center" valign="middle" rowspan="1" colspan="1">69.9</td><td align="center" valign="middle" rowspan="1" colspan="1">2.98 (overlap)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4&#x02032;</td><td align="center" valign="middle" rowspan="1" colspan="1">80.4</td><td align="center" valign="middle" rowspan="1" colspan="1">3.63 (overlap)</td><td align="center" valign="middle" rowspan="1" colspan="1">78.5</td><td align="center" valign="middle" rowspan="1" colspan="1">3.70 (dd, 9.6, 7.3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5&#x02032;</td><td align="center" valign="middle" rowspan="1" colspan="1">73.5</td><td align="center" valign="middle" rowspan="1" colspan="1">3.54&#x02013;3.60 (m)</td><td align="center" valign="middle" rowspan="1" colspan="1">73.5</td><td align="center" valign="middle" rowspan="1" colspan="1">3.52&#x02013;3.56 (m)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6&#x02032;</td><td align="center" valign="middle" rowspan="1" colspan="1">19.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.34 (d, 6.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">19.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.36 (d, 6.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7&#x02032; and 8&#x02032;</td><td align="center" valign="middle" rowspan="1" colspan="1">41.8</td><td align="center" valign="middle" rowspan="1" colspan="1">2.59(s)</td><td align="center" valign="middle" rowspan="1" colspan="1">41.9</td><td align="center" valign="middle" rowspan="1" colspan="1">2.68 (s)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1&#x02033;</td><td align="center" valign="middle" rowspan="1" colspan="1">99.0</td><td align="center" valign="middle" rowspan="1" colspan="1">5.16 (overlap)</td><td align="center" valign="middle" rowspan="1" colspan="1">98.7</td><td align="center" valign="middle" rowspan="1" colspan="1">5.17 (overlap)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2&#x02033;</td><td align="center" valign="middle" rowspan="1" colspan="1">43.0</td><td align="center" valign="middle" rowspan="1" colspan="1">2.06 (d, 15.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">42.8</td><td align="center" valign="middle" rowspan="1" colspan="1">2.06 (dd, 14.5, 4.6)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1.96 (dd, 14.4, 4.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1.97 (d, 14.1)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3&#x02033;</td><td align="center" valign="middle" rowspan="1" colspan="1">70.4</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">70.6</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4&#x02033;</td><td align="center" valign="middle" rowspan="1" colspan="1">78.6</td><td align="center" valign="middle" rowspan="1" colspan="1">4.60 (d, 10.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">78.5</td><td align="center" valign="middle" rowspan="1" colspan="1">4.62 (d, 9.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5&#x02033;</td><td align="center" valign="middle" rowspan="1" colspan="1">65.0</td><td align="center" valign="middle" rowspan="1" colspan="1">4.43&#x02013;4.47 (m)</td><td align="center" valign="middle" rowspan="1" colspan="1">65.1</td><td align="center" valign="middle" rowspan="1" colspan="1">4.37 (overlap)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6&#x02033;</td><td align="center" valign="middle" rowspan="1" colspan="1">17.9</td><td align="center" valign="middle" rowspan="1" colspan="1">1.11 (s)</td><td align="center" valign="middle" rowspan="1" colspan="1">17.9</td><td align="center" valign="middle" rowspan="1" colspan="1">1.13 (d, 2.3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7&#x02033;</td><td align="center" valign="middle" rowspan="1" colspan="1">26.8</td><td align="center" valign="middle" rowspan="1" colspan="1">1.13 (s)</td><td align="center" valign="middle" rowspan="1" colspan="1">26.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1.14 (s)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">8&#x02033;</td><td align="center" valign="middle" rowspan="1" colspan="1">175.8</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">175.8</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">9&#x02033;</td><td align="center" valign="middle" rowspan="1" colspan="1">28.3</td><td align="center" valign="middle" rowspan="1" colspan="1">2.45 (overlap)</td><td align="center" valign="middle" rowspan="1" colspan="1">28.3</td><td align="center" valign="middle" rowspan="1" colspan="1">2.46 (overlap)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10&#x02033;</td><td align="center" valign="middle" rowspan="1" colspan="1">9.6</td><td align="center" valign="middle" rowspan="1" colspan="1">1.20</td><td align="center" valign="middle" rowspan="1" colspan="1">9.6</td><td align="center" valign="middle" rowspan="1" colspan="1">1.21 (overlap)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1&#x02034;</td><td align="center" valign="middle" rowspan="1" colspan="1">107.8</td><td align="center" valign="middle" rowspan="1" colspan="1">4.40 (dd, 7.8, 7.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">107.8</td><td align="center" valign="middle" rowspan="1" colspan="1">4.88 (d, 7.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2&#x02034;</td><td align="center" valign="middle" rowspan="1" colspan="1">76.5</td><td align="center" valign="middle" rowspan="1" colspan="1">3.21 (dd, 8.4, 8.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">76.1</td><td align="center" valign="middle" rowspan="1" colspan="1">3.21 (dd, 9.0, 7.6)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3&#x02034;</td><td align="center" valign="middle" rowspan="1" colspan="1">77.8</td><td align="center" valign="middle" rowspan="1" colspan="1">3.38 (dd, 9.0, 9.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">78.0</td><td align="center" valign="middle" rowspan="1" colspan="1">3.35 (overlap)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4&#x02034;</td><td align="center" valign="middle" rowspan="1" colspan="1">71.3</td><td align="center" valign="middle" rowspan="1" colspan="1">3.34 (overlap)</td><td align="center" valign="middle" rowspan="1" colspan="1">71.1</td><td align="center" valign="middle" rowspan="1" colspan="1">3.46 (overlap)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5&#x02034;</td><td align="center" valign="middle" rowspan="1" colspan="1">78.5</td><td align="center" valign="middle" rowspan="1" colspan="1">3.29 (overlap)</td><td align="center" valign="middle" rowspan="1" colspan="1">67.5</td><td align="center" valign="middle" rowspan="1" colspan="1">3.90 (overlap)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">3.2 (overlap)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6&#x02034;</td><td align="center" valign="middle" rowspan="1" colspan="1">62.9</td><td align="center" valign="middle" rowspan="1" colspan="1">3.89 (overlap)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.76 (dd, 12.0, 4.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="ijms-22-12636-t002"><object-id pub-id-type="pii">ijms-22-12636-t002_Table 2</object-id><label>Table 2</label><caption><p>Kinetic parameters for OleD-catalyzed glucosylation towards midecamycin.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Substrate</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">K</italic><sub>m</sub> (mM)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">V<sub>max</sub> (mM/min)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">UDP-Glc</td><td align="center" valign="middle" rowspan="1" colspan="1">1.933 &#x000b1; 0.124</td><td align="center" valign="middle" rowspan="1" colspan="1">0.080 &#x000b1; 0.002</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">midecamycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.626 &#x000b1; 0.106</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.120 &#x000b1; 0.830</td></tr></tbody></table></table-wrap><table-wrap position="float" id="ijms-22-12636-t003"><object-id pub-id-type="pii">ijms-22-12636-t003_Table 3</object-id><label>Table 3</label><caption><p>Antimicrobial activity of midecamycin 2&#x02032;-<italic toggle="yes">O</italic>-glycosides against microorganisms.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Strain</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">MIC (&#x003bc;g/mL)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Midecamycin</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1a</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1c</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1g</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Bacillus intestinalis</italic> strain T30</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Bacillus subtilis</italic> strain 168</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus aureus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Streptococcus pneumoniae</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.25</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Pseudomonas aeruginosa</italic> PAO1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Escherichia coli</italic> DH5&#x003b1;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02014;</td></tr></tbody></table></table-wrap></floats-group></article>